Document:

Exhibit 10.21

 

DISTRIBUTION AGREEMENT

Proprietary and Confidential

 

THIS DISTRIBUTION AGREEMENT (“Agreement”)
is made effective as of the 21 day of April, 2020 (“Effective Date”) and is entered into by and between;

 

G Medical Innovations, Ltd. (“G MEDICAL”),
Company No._______________, a limited liability company, having its principal place of business at, 5, Oppenheimer St. Rehovot,
7670105, Israel, and

 

Home
Service Solutions Pty Ltd (“HSS”),
Company No. 616 760 171, a limited liability company, having its principal place of business at, L 2, 22 Mount Street, Perth,
Western Australia. (“Distributor”).

 

G MEDICAL and Distributor are hereinafter sometimes referred
to individually as a “Party” and collectively as the “Parties”.

 

WHEREAS, G MEDICAL is in the business
of developing and offering mobile health and e-health solutions and products;

 

WHEREAS, Distributor desires to purchase
products from G MEDICAL from time to time, for distribution, sale and resale to end user consumers and entities located in the
Territory (as defined below); and

 

WHEREAS, the Parties desire to enter
into a distributor relationship, pursuant to the governing terms and mutual promises which are set out in this Agreement.

 

NOW, THEREFORE, in consideration
of the mutual promises contained herein and intending to be legally bound, G MEDICAL and Distributor agree as follows:

 

1. PRODUCT DISTRIBUTION
RIGHTS

 

1.1 Purpose of this Agreement. The
purpose of this Agreement is to set forth the respective duties and obligations of G MEDICAL and Distributor with respect to the
distribution of products and services offered by G MEDICAL from time to time as described in Exhibit A (“Products”).

 

1.2 Appointment/Obligation
of Distributor. Subject to the terms and conditions of this Agreement, G MEDICAL hereby appoints Distributor for the term of
this Agreement as a non-exclusive distributor of the Products within the geographic area and restrictions described in Exhibit
B (the “Territory”). Distributor accepts this appointment upon the terms and conditions herein and agrees
that for the term of this Agreement Distributor will: (a) use its best commercial efforts to develop business in, to promote
the sale of, and to sell the Products in the Territory; (b) maintain a representative and adequate inventory of Products and include
a representative listing of Products in any catalog Distributor may issue for use or distribution in the Territory; (c) provide
on a periodic basis such information and reports of inventories, sales and other pertinent information as G MEDICAL in the reasonable
exercise of its judgment may from time to time request; (d) Keep an updated list of all end user consumers and entities (“End
Users”) (including End User’s name, address and contact details), which have purchased the Products and shall supply
a copy of such list from time to time promptly following G MEDICAL’s written request; and (e) take reasonable, good faith
action in communicating and carrying out advertising and promotional programs and services within the Territory.

 

1.3 Distributor
shall, in addition to the above: (a) bear all responsibility for and risk of sales to End Users, invoicing its End Users, extending
credit to its End Users, collection of sales tax, collection of receivables from its End Users, distribution costs and the like;
(b) conduct the business pursuant to this Agreement in an ethical, orderly and businesslike manner and strictly in compliance with
the provisions hereof; (c) not make any representations or give any warranties with regard to the Products, except as provided
by G Medical; (d) not, during the term of this Agreement and for a period of twelve (12) months following the expiration or termination
of this Agreement for any reason - manufacture, market, distribute or sell, or gain a financial interest in or otherwise be involved,
either directly or indirectly, in any business which is involved in the development, marketing or sale, of goods which are identical
or similar to the Products, or any other services which relate to the Products, within the Territory, other than the Products under
this Agreement; (e) not, by act or omission, harm or damage the goodwill of G MEDICAL and/or its business; (f) obtain and maintain
throughout the term of this Agreement, all permits, licenses and authorizations that may be necessary under any applicable
law, agreement or otherwise, for the performance of this Agreement; and (g) inform G MEDICAL promptly of any claim by an End User
and the way it was handled by the Distributor.

 

     
 

     
G MEDICAL Distribution Agreement Proprietary and Confidential

    

 

1.4 Products. The Products available
for distribution and resale within the Territory shall be as set forth on Exhibit A, which may be amended or modified from
time to time by G MEDICAL.

 

1.5 Permitted Distribution and Restrictions.
Distributor may only resell and distribute the Products in the Territory and in no other geographic region. Distributor shall not
directly or indirectly (i) engage in the promotion of the Products outside the Territory; (ii) transship, convey, gift, sell or
otherwise transfer the Products outside the Territory, and/or (iii) sell Products to any person or entity that intends to sell
the Products outside the Territory; unless explicitly authorized in advance by G MEDICAL in writing. Exhibit B may be amended
by G MEDICAL from time to time upon providing thirty (30) days prior written notice to Distributor.

 

1.6 Non-Exclusivity.

 

The appointment of
the Distributor hereunder is on a non-exclusive basis and G MEDICAL may enter into similar and/or competing arrangements with other
parties.

 

Without derogating
from the above, Distributor shall, during the term of this Agreement, immediately advise G MEDICAL, in writing, should it encounter
any potential or actual conflict with G MEDICAL’s interests hereunder.

 

2. TERM AND TERMINATION

 

2.1 Term. The initial term of this
Agreement is one (1) year from the Effective Date, unless terminated earlier pursuant to the terms and conditions set forth in
this Agreement. Thereafter the Agreement will automatically renew for successive one (1) year terms, unless either Party provides
written notice of its intent not to renew this Agreement at least thirty (30) days prior to the applicable anniversary date.

 

2.2 Termination. This Agreement
shall terminate upon thirty (30) days advance written notice by G MEDICAL. Notwithstanding the above, G MEDICAL may terminate this
Agreement immediately if the Distributor is in breach of any of the terms and conditions in this Agreement or in the event Distributor
ceases to conduct business in the normal course, becomes insolvent, makes a general assignment for the benefit of creditors, suffers
or permits the appointment of a receiver for its business or assets, or avails itself of or becomes subject to any proceeding under
any applicable bankruptcy or insolvency law.

 

2.3 Effect of Termination; Survival.

 

Upon expiration or termination for any reason of this Agreement,
the following will apply:

 

(a) The appointment of Distributor as a
distributor of G MEDICAL under Section 1.2 above shall terminate on the effective date of termination;

 

(b) The Distributor shall immediately (i)
cease to conduct the business pursuant to this Agreement and to represent itself as a Distributor of G MEDICAL; (ii) cease to make
use of G MEDICAL’s Intellectual Property, and shall immediately sign all the necessary documents for cancellation of the
Marks license as recorded in the Territory; (iii) cease to use, and shall deliver to G MEDICAL, any unused sales literature and
other written information and materials supplied by G MEDICAL pursuant to this Agreement or which contain G MEDICAL’s Marks
and any other of G MEDICAL’s Intellectual Property Rights; and (iv) return to G MEDICAL any G MEDICAL Confidential Information
disclosed to it in writing or in any other tangible form.

 

    		Page 2 of 17	 

     
G MEDICAL Distribution Agreement Proprietary and Confidential

    

 

(c) Any amounts owed by the Distributor
pursuant to this Agreement shall become immediately due and payable. The Distributor shall promptly make any and all outstanding
payments to G MEDICAL within no more than seven (7) days from the expiration or termination date;

 

(d) G MEDICAL shall have no obligation
to compensate the Distributor for the expiration or termination of this Agreement, including but not limited to, any costs, fees
and expenses which the Distributor has incurred in connection with this Agreement and/or the conducting the business pursuant thereto,
and the Distributor hereby waives any and all rights to damages or any other remedies that the Distributor might otherwise have
upon any expiration or termination of this Agreement;

 

(e) Termination shall not derogate from
rights and obligations accrued prior to the effective date of termination, and shall not relieve Distributor from any payment obligations
hereunder that remain unpaid, or limit either Party from pursuing other available remedies, provided that G MEDICAL’s total
liability shall be limited as set out in Section 16.5 above; and

 

The provisions of Sections 4, 8, 9, 12 through and including
16 hereto, shall survive the expiration or termination of this Agreement for any reason, together with such other provisions necessary
to give effect to such provisions.

 

3. ROLLING FORECAST
AND PURCHASE ORDERS

 

3.1 Forecasts.
Distributor will deliver to G MEDICAL a thirty-six (36) month rolling forecast per model on a monthly basis in writing based
on Distributor’s anticipated requirements for Products (each a “Forecast”). The first Forecast will be
submitted thirty (30) days after state regulatory approval. The first twelve (12) months of the Forecast shall be binding,
and the remainder of the Forecast shall be non-binding. The Forecast shall specify the quantity of each type of Products that the
Distributor expects to purchase on a month-to-month basis during the Forecast period.

 

3.2 Purchase Orders. All purchases
of Products shall be initiated by Distributor’s issuance of a purchase order sent in writing or, if available, via electronic
data interchange to G MEDICAL (“Purchase Order(s)”). Distributor’s legal entity name, which shall be identical
to the signing party of this Agreement shall be listed under the “bill to” name on the Purchase Order for billing purposes.
Distributor shall issue the Purchase Orders Not later than sixteen (16) weeks prior to the requested ship date. Such orders
shall identify the quantity and type of Products desired and the requested ship dates. G MEDICAL shall use reasonable efforts to
notify Distributor of the acceptance or rejection of each Purchase Order within seven (7) days of its receipt. Upon Purchase
Order acceptance, G MEDICAL shall provide Distributor with a committed ship date within seven (7) days. The individual contracts
for the sale of Products formed by Distributor’s submission of Purchase Orders to G MEDICAL pursuant to the terms and conditions
hereof shall automatically incorporate, to the extent applicable, the terms and conditions of this Agreement, shall be subject
only to those terms and conditions contemplated by this Agreement and shall not be subject to any conflicting or additional terms
included in any documents exchanged in connection therewith. Other than as expressly provided for herein, the terms and conditions
on any Purchase Order issued by Distributor are null and void and shall have no force or effect whatsoever.

 

3.3 Purchase Order Processing. G
MEDICAL reserves the right to reject any Purchase Order in whole or in part, and delivery of part of an order shall not obligate
G MEDICAL to make further deliveries. A Purchase Order shall be considered accepted by G MEDICAL only by one of the following means:
(a) issuance of an acknowledgement in writing by G MEDICAL’s authorized representative; or (b) shipment of Products ordered
to the extent such Products are shipped.

 

3.4 Purchase Order Cancellation.
All cancellation of Purchase Orders by Distributor shall be in writing and are available only for Purchase Orders not yet shipped.
If Distributor cancels a Purchase Order, which has been accepted by G MEDICAL, Distributor shall reimburse G MEDICAL at its first
demand for any cost incident to such Purchase Order incurred by G MEDICAL prior to the time it was informed of the cancellation.

 

3.5 Field Replacement Units. G MEDICAL
shall provide Distributor free of charge an extra supply of Products (handset and battery only or wireless device only) equal to
Five percent (5%) of all Distributor Purchase Orders (“FRU”) which Distributor shall use for replacement purpose
of any units sold by Distributor are returned.

 

    		Page 3 of 17	 

     
G MEDICAL Distribution Agreement Proprietary and Confidential

    

 

Any replaced Unit shall be returned to
G Medical for investigation and analysis of the problem led to the Unit replacement. Distributor shall maintain a monthly RMA shipment
of replaced product. Notwithstanding anything in this Agreement to the contrary, except for FRU, G MEDICAL shall not be obligated
to provide any additional replacement or other “free” units to Distributor or its customers, even if any such returned
Product is under warranty.

 

4. PRICING TERMS

 

Pricing of Products to be purchased by
Distributor shall be at the prices as determined by the G MEDICAL from time to time. G MEDICAL reserves the right, in its sole
discretion, to change prices or discounts applicable to the Products. G MEDICAL shall give written notice to Distributor of any
price change at least thirty (30) days prior to applying such price change.

 

Subject to applicable law, G MEDICAL shall
have the right, but not the obligation, to determine pricing at which Distributor offers Products to its customers, provided, however,
that if G MEDICAL shall exercise this right, it shall account for Distributor to make a reasonable profit from its sales based
on market profit.

 

Neither Distributor and/or any third party
shall be entitled to any payment whatsoever (including, without limitation, any reimbursement of expenses) from G MEDICAL for any
activities of Distributor performed in accordance with this Agreement, which shall be deemed to be made at Distributor’s
own risk, liability and expense.

 

5. DELIVERY AND RISK OF LOSS; OWNERSHIP

 

All deliveries of Products sold by G MEDICAL
to Distributor pursuant to this Agreement shall be made FCA (Incoterms 2010). Risk of loss of Products shall pass from G MEDICAL
to Distributor once the Products are picked up by the Distributor at the loading area in G Medical distribution center in
Israel and/or in the European Union (the “Delivery Point”). Distributor shall be responsible for arranging all
transportation of Products, but if requested by Distributor, G MEDICAL shall, at Distributor’s sole expense, assist Distributor
in making such arrangements. Distributor shall also procure, at its own expense, insurance for the transportation of the Products,
and such insurance shall be of a kind and on terms current at the port of shipment. Distributor shall pay any and all charges,
including port, customs and forwarding fees if applicable and any and all sales tax, incurred with respect to the Products following
their Delivery to the Delivery Point.

 

All losses and damages to the Products
occurring prior the arrival of the Products to the Delivery Point shall be G MEDICAL’s liability, and all losses and damages
to the Products occurring after such point shall be Distributor’s liability.

 

Without limitation to the above, the transfer
of ownership to the applicable Products shall be effective only after receipt by G MEDICAL of full payment therefor.

 

6. PRODUCT PACKAGING

 

G MEDICAL shall, at its expense, pack all
Products in accordance with G MEDICAL’s standard packing procedure, which shall be suitable to permit shipment of the Products
to the Territory; provided, however, that if Distributor requests a modification of those procedures, G MEDICAL shall make the
requested modification and Distributor shall bear any and all expenses incurred by G MEDICAL in complying with such modified procedures
which are in excess of the expenses which G MEDICAL would have incurred in following its standard procedures.

 

7. INSPECTION, ACCEPTANCE AND WARRANTY

 

7.1 Promptly
upon the receipt of a shipment of Products, Distributor shall examine the shipment to determine whether any item or items included
in the shipment are in short supply, defective or damaged. Within seven (7) days of receipt of the shipment, Distributor shall
notify G MEDICAL in writing of any shortages, defects or damage which Distributor claims existed at the time of delivery. The shipment
shall be deemed accepted as is for any portion (if Distributor notifies G MEDICAL of a problem with a portion of the shipment)
or the entire shipment, in each case if Distributor fails to timely notify G MEDICAL in writing of any concern or issue.
Within fifteen (15) days after the receipt of such notice, G MEDICAL will investigate the claim of shortages, defects or damage,
inform Distributor of its findings, and thereafter deliver to Distributor Products to replace any which G MEDICAL determines, in
its sole discretion, were in short supply, defective or damaged at the time of delivery, and rectify as G MEDICAL deems appropriate
in its sole discretion if G MEDICAL determines that a shipment as delivered was inadequate.

 

    		Page 4 of 17	 

     
G MEDICAL Distribution Agreement Proprietary and Confidential

    

 

7.2 G Medical shall replace at its expense
any Products sold to End Users found defective by Distributor during a warranty period of 12 months and returned to Distributor
for repair. Return of the replacement Products to Distributor’s original destination shall be at the expense of G Medical,
unless G Medical determines that the Product is not defective within the terms of the warranty, in which event Distributor shall
pay G Medical all costs of handling, transportation and labor at G Medical’s then prevailing rates.

 

		7.3	The distributor will maintain records of all complaints, oral or written, received from customers.
Such complaints will be notified to the manufacturer for investigation and handling within 24 hours and will be handled by the
distributor within 5 working days (in order to complete the handling process).
	 	 	 

		7.4	The distributor will maintain records of the distribution of medical devices to allow traceability
and allow these records to be available for inspection: Supplied product, serial number of the product (if applicable) name and
address of the customer, date of shipment, quantity shipped. The records shall be retained for at least seven years back; this
is necessary for quick and effective retrieval of distribution records in the event that the product is subject to Recall and/
Advisory Notice.
	 	 	 

		7.5	The distributor undertakes to store the product according to the environmental conditions specified
by the manufacturer (applicable to the patch).
	 	 	 

		7.6	The distributor will not perform any repackaging or relabeling for the product unless authorized
to do so in writing by the manufacturer.

 

7.7 Limitation on Warranties. Warranties
and Distributor’s remedies hereunder are solely for the benefit of Distributor and shall not be extended to any person whatsoever,
it being understood that the warranty to Distributor hereunder shall survive the sale or transfer of the Products. This warranty
shall not apply to any Product that (a) has been damaged by misuse, accident, neglect, or from any other cause beyond G Medical’s
reasonable control, including force majeure, and without G Medical’s fault or omission or negligence or the fault or negligence
or omission of G Medical; or (b) has been used in a manner not in accordance with the instructions supplied by G Medical.

 

7.8 THE WARRANTIES
PROVIDED IN THIS SECTION 7 CONSTITUTE G MEDICAL’S SOLE AND EXCLUSIVE LIABILITY FOR DEFECTIVE OR NONCONFORMING PRODUCT AND
SHALL CONSTITUTE DISTRIBUTOR’S SOLE AND EXCLUSIVE REMEDY FOR DEFECTIVE OR NONCONFORMING PRODUCT. THESE WARRANTIES ARE IN
LIEU OF ALL OTHER WARRANTIES EXPRESS OR IMPLIED OR STATUTORY, INCLUDING, BUT NOT LIMITED TO, IMPLIED WARRANTIES OF MERCHANTABILITY
OR FITNESS FOR A PARTICULAR PURPOSE, AND ARE IN LIEU OF ALL OBLIGATIONS OR LIABILITIES ON THE PART OF G MEDICAL FOR DAMAGES.

 

8. INVOICING AND PAYMENT

 

8.1 Prior to the delivery and/or acceptance
of Products, G MEDICAL may submit to Distributor G MEDICAL’s invoice for those Products. All payments shall be made in United
States Dollars (USD). All payments by Distributor must be made by wire transfer to G MEDICAL’s bank account unless there
is a letter of credit in which case the Distributor’s bank shall make payment. Distributor shall complete any G MEDICAL provided
credit application and financial statements, if requested by G MEDICAL. Payment shall be made by option (a) or (b) set
forth below:

 

(a)
For each and every Distributor Purchase Order submitted according to Section 3.2, Distributor shall deliver to G MEDICAL, as collateral
for the full and faithful performance by Distributor of all of its obligations under this Agreement, an irrevocable and unconditional
negotiable letter of credit, (the “Letter of Credit”) in the amount of the Purchase Order, payable at sight, from a
reputable bank acceptable to G MEDICAL. The Letter of Credit must be issued and confirmed seventy five (75) days prior to
the shipment date. In addition to the foregoing, the form and terms of the Letter of Credit (and the bank issuing the same) shall
be acceptable to G MEDICAL, in G MEDICAL’s sole discretion, and shall provide, among other things, that such Letter of Credit
shall be irrevocable, unconditional, and payable at sight; or

 

    		Page 5 of 17	 

     
G MEDICAL Distribution Agreement Proprietary and Confidential

    

 

(b) For the initial year of the
term, for each and every Distributor Purchase Order submitted according to Section 3.2, Distributor shall (i) wire thirty (30%)
of the total Purchase Order amount seventy five (75) days before shipment; and (ii) wire the remaining seventy percent
(70%) of the total Purchase Order amount of the Product ten (10) days before shipment. For each year of the term following
the initial year of the term, for each and every Distributor Purchase Order submitted according to Section 3.2, Distributor shall
(i) wire twenty percent (20%) of the total Purchase Order amount seventy five (75) days before shipment; and (ii)
wire the remaining eighty percent (80%) of the total Purchase Order amount of the Product ten (10) days before shipment

 

8.2 The payment terms allowed by G MEDICAL
may be subject to change based upon the financial condition of Distributor.

 

8.3 Distributor will be responsible for
obtaining all governmental and other approvals and complying with all formalities needed to effectuate any and all payments to
G MEDICAL as provided herein.

 

8.4 Distributor shall not be entitled to
withhold or delay any payment due to G MEDICAL hereunder, and shall not set off or deduct therefrom any amounts whatsoever.

 

8.5 All fees due to G MEDICAL hereunder
are net and are exclusive of all current and future taxes, including without limitation, sales, use, value-added, withholding or
other taxes, customs duties or levies on transactions made under this Agreement, all of which (except for taxes on the income of
G Medical) shall be borne by the Distributor.

 

9. ADVERTISING AND
TRADEMARK USE

 

9.1 Use
and Ownership of Marks. Distributor recognizes and acknowledges G MEDICAL’s ownership and title to its respective trademarks,
service marks, corporate slogans or logos and trade names whether or not registered (“Marks”). Distributor shall
use the Marks solely to identify the Products for purposes of Distributor’s performance under this Agreement . Distributor
may not use G MEDICAL the Marks in advertising, promotion, and publicity of the Products without the express written consent of
G MEDICAL. All permitted uses of the Marks shall be deemed to be a license thereof by G MEDICAL upon the provisions specified in
Section 1.2 above, and Distributor shall not acquire any rights, title, or interest in the Marks nor will it act to impair the
rights of G MEDICAL in such Marks, except for such rights of usage as may be permitted by this Section 9.1. Distributor
shall not adopt, use or register any names or symbols that are identical, or confusingly similar, to the Marks. Furthermore, the
Distributor shall not, directly or indirectly, at any time and in any jurisdiction, (i) use any of the Marks for any other purpose
except for the marketing of the Products as expressly allowed hereunder, (ii) attempt to misappropriate, circumvent or violate
any of G MEDICAL’s Intellectual Property, or other interests in the Products, (iii) dilute, damage or endanger the distinctiveness
of a Marks or depreciate the value attached thereto, nor (iv) modify, translate, or prepare derivative works based on the Marks.
The Distributor shall provide G MEDICAL, at G MEDICAL’s expense, with any assistance it may require in connection with the
registration of the Marks and the Marks license granted hereunder in the Territory. The Distributor hereby irrevocably designates
and appoints G MEDICAL as the Distributor’s agent and attorney-in-fact, at G MEDICAL’s sole discretion - to act for
and on the Distributor’s behalf and instead of the Distributor, to execute and file any such documents and to do all other
lawfully permitted acts to further the purposes of registration of the Marks and the Marks license granted hereunder in the Territory,
with the same legal force and effect as if executed by the Distributor.

 

9.2 Advertisements
Guidelines. Distributor shall submit examples of all proposed advertisements and other promotional materials for the Products
to G MEDICAL for inspection and Distributor shall not use any such advertisements or promotional materials without having received
the prior written consent of G MEDICAL to do so. The Distributor shall singly meet and bear all costs related to advertising and
marketing. However, G MEDICAL, in its sole discretion, may from time to time determine the nature or extent of its support
(if any) towards the marketing or advertising costs of the Distributor.

 

    		Page 6 of 17	 

     
G MEDICAL Distribution Agreement Proprietary and Confidential

    

 

9.3 Distributor acknowledges and agrees
that G MEDICAL shall have the right to (a) engage in quality control activities designed to protect G MEDICAL’s legal ownership
rights in its Marks and (b) engage in activities designed to ensure that Distributor is conducting its resale activities and other
operations in full compliance with this Agreement.

 

10. DISTRIBUTOR SALES AND STORAGE FACILITIES

 

Distributor shall, at its expense, at all
times store and maintain its inventory of Products in accordance with current, applicable instructions issued by G MEDICAL from
time to time. Distributor shall, at its expense, deliver one copy of G MEDICAL’s current, applicable operation and maintenance
manual to each End User at the time of sale and, at that time, Distributor shall, at its expense, fully explain and demonstrate
to the End User the proper method of operating and maintaining the Products. Distributor shall mail to G MEDICAL, during the term
of this Agreement, prompt written notice of the address of each location at which Products are stored, and the address of each
facility established by Distributor to sell the Products. G MEDICAL may, through its designated agent, inspect all such locations
and facilities and the operations conducted therein at any time during normal business hours.

 

11. TRAINING OF DISTRIBUTOR

 

As promptly as practicable after execution
of the Agreement, G MEDICAL shall transmit to Distributor information, materials, manuals and other technical documents deemed
necessary and appropriate by G MEDICAL to enable Distributor to perform its obligations under this Agreement. Throughout the term
of this Agreement, G MEDICAL shall continue to give Distributor such technical assistance as Distributor may reasonably request.
Distributor shall reimburse G MEDICAL for all out-of-pocket expenses incurred by G MEDICAL in providing technical assistance.

 

12. RELATIONSHIP OF PARTIES

 

12.1 Distributor is an independent contractor
and is not the legal representative, employee, partner, franchisee or agent of G MEDICAL for any purpose and shall have no right
or authority (except as expressly provided in this Agreement) to incur, assume or create in writing or otherwise, any obligation
of G MEDICAL.

 

12.2 Distributor shall, at its own expense,
during the term of this Agreement and any extension thereof, maintain full insurance under any Workmen’s Compensation Laws
effective in the Territory covering all persons employed by and working for it in connection with the performance of this Agreement,
and upon request shall furnish G MEDICAL with satisfactory evidence of the maintenance of such insurance.

 

12.3 Distributor will be solely responsible
for payment of all compensation owed to its employees, as well as employment-related taxes. Distributor accepts exclusive liability
for all contributions and payroll taxes required under the laws of the Territory or other payments under any laws of similar character
in any applicable jurisdiction as to all persons employed by and working for it. There shall be no employer-employee relationship
between the Parties and/ or the Parties’ employees.

 

12.4 Nothing contained in this Agreement
shall be deemed to create any partnership or joint venture relationship between the Parties.

 

13. REPRESENTATIONS AND WARRANTIES

 

13.1 Mutual Representations and Warranties.
Each Party hereby represents and warrants that:

 

		(a)	It has all requisite corporate power and authority to execute, deliver, and perform its obligations
under this Agreement;
	 	 	 

		(b)	Its signing of, and agreement to, this Agreement have been duly authorized by all requisite corporate
actions;
	 	 	 

		(c)	This Agreement is a valid and legally binding obligation thereon, enforceable against it in accordance
with its terms; and

 

    		Page 7 of 17	 

     
G MEDICAL Distribution Agreement Proprietary and Confidential

    

 

		(d)	Nothing contained in this Agreement or the performance thereof shall place the relevant Party in breach
or default of any obligation or other agreement, law or regulation by which it is bound or to which it is subject, or requires
the consent of any person or entity.

 

13.2 Distributor’s Representations.
In addition to and without derogating from the provisions of Section 13.1 above, Distributor hereby represents, warrants and covenants
that:

 

		(a)	It shall perform its obligations hereunder in full compliance with all applicable laws and regulations.
Such laws, regulations shall include, without limitation, tender and bidding laws, anti-corruption and anti-unfair competition
laws and regulations. The Distributor hereby acknowledges that it is fully aware of all the above-mentioned laws and regulations
and any possible violation of such laws and regulations by the Distributor, shall be the sole responsibility of the Distributor.
The Distributor shall indemnify and hold the G MEDICAL harmless from any and all loss or damage sustained because of the Distributor’s
non-compliance with any applicable laws and regulations;

 

		(b)	It has the required experience, expertise, personnel, facilities and resources in order to perform
all of Distributor’s obligations under this Agreement. Distributor’s personnel involved in performing its obligations
hereunder shall have sufficient skill, knowledge, and training to perform such services and carry out their assignments hereunder
and shall perform their tasks in a professional and workmanlike manner, consistent with the performance standards set out in this
Agreement, and at least in accordance with generally accepted industry standards;

 

		(c)	no monies have been or shall, directly or indirectly, be paid or offered by it or on its behalf to
any Government Authority (as defined below), or to any Government Officials (as defined below), for the purpose of improperly obtaining,
retaining or directing any business opportunity related to this Agreement.

 

For the purpose of this Section
13.2(c) –

 

		(i)	“Government” or “Government Authority” means any governmental
agency or instrumentality, government owned or controlled entity such as a state-owned or controlled company, political Party,
and/or public international organization; and
	 	 	 

		(ii)	“Government Officials” means any representatives, officers and/or employees
of any of the aforementioned entities mentioned in the definition of “Government”, including (without limitation) a
candidate of a political Party.

 

In addition, the Distributor hereby
represents and warrants that (i) it is not beneficially owned or controlled, directly or indirectly, by any Government Authority
or Government Official; (ii) that there are no actual or threatened legal proceedings and/or investigations of any Government Authority,
judicial or other competent authority against the Distributor, whether within the Territory or outside its borders; and (iii) that
there is no family relationship between the Distributor and Government Officials.

 

Any breach by Distributor of any
undertaking in this Section 13.2(c) shall be deemed a material breach of this Agreement and any contract or business relationship
between Distributor and G MEDICAL, and, notwithstanding anything to the contrary contained in Section 16 below, shall entitle G
MEDICAL to terminate this Agreement and any such other contract or business relationship immediately. Such right of termination
for breach shall be in addition and without prejudice to any other rights and remedies which G MEDICAL may have in contract and/or
at law with respect to such breach.

 

14. INTELLECTUAL PROPERTY

 

The Distributor hereby acknowledges and
agrees that all right, title, and interest in and to, G MEDICAL’s Intellectual Property, are and shall remain the sole and
exclusive property of G MEDICAL. Distributor is granted no title or ownership rights in or to G MEDICAL’s Intellectual Property.

 

    		Page 8 of 17	 

     
G MEDICAL Distribution Agreement Proprietary and Confidential

    

 

Without derogating from the above, G MEDICAL
reserves all proprietary rights in and to (i) all designs, engineering details and other data pertaining to the Products, (ii)
all original works, computer programs, discoveries, inventions, patents, know-how, and techniques arising out of, and/or (iii)
any and all products or services developed as a result of, the Products.

 

For the purposes of this Agreement:

 

“Intellectual Property”
means all intellectual, moral, industrial and/or proprietary property and rights now or hereafter recognized under any applicable
law or in equity anywhere in the world, whether issued or pending, registered or unregistered, including, but not limited to (i)
all forms of patents and utility models; (ii) inventions, discoveries, (whether patentable or not); (iii) rights associated with
works of authorship, including but not limited to copyrights and maskworks; (iv) trademarks and service marks, trade names, domain
name registration; (v) designs (whether or not capable of registration), design rights; (vi) database rights; (vii) trade secrets
and know how; (viii) all rights to confidential or proprietary information; and with respect to the intellectual property included
in paragraphs (i) to and including (viii) above - any rights analogous to those mentioned herein; all derivative works thereof;
and any current or future applications, renewals, extensions, restorations, provisionals, continuations, continuations-in-part,
divisions, reexaminations and reissues thereof; the right to apply to any of the above; and all of the tangible embodiments thereof.

 

“Intellectual Property Rights”
means all rights, title and interest in and to any Intellectual Property.

 

14.1 All rights not expressly granted to
Distributor in this Agreement are retained by G MEDICAL. Section 1.2 above sets out Distributor’s sole right with respect
to the Products.

 

In no event shall Distributor have any
other right with respect to the Products, including, without limitation, a right, permission or license to use the same or any
part thereof for any purpose whatsoever.

 

The Distributor acknowledges and agrees
that it neither possesses nor will seek any rights in G MEDICAL’s Intellectual Property.

 

14.2 Any goodwill associated with or created
with respect to the Products and the Marks in the Territory or elsewhere as a result of the Distributor’s performance of
this Agreement, shall be owned solely by G MEDICAL, and Distributor hereby irrevocably waives any demand or claim in this respect.
Without limiting the generality of the above, the Distributor hereby irrevocably and unconditionally assigns to G MEDICAL (and/or
such other third party as shall be instructed by G MEDICAL) all goodwill in and to the Products and the Marks created in connection
with the performance of the Distributor’s obligations hereunder.

 

14.3 Distributor shall promptly notify
G MEDICAL in writing of any infringement or other violation of G MEDICAL’s Intellectual Property Rights to which Distributor
becomes aware.

 

G MEDICAL shall have the sole and exclusive
right to protect and defend G MEDICAL’s Intellectual Property Rights, at its sole cost and expense. Distributor shall reasonably
cooperate with G MEDICAL, at G MEDICAL’s expense, in the defense and protection of such Intellectual Property Rights.

 

15. CONFIDENTIAL
INFORMATION

 

15.1 G MEDICAL
and Distributor acknowledge that certain non-public, proprietary, or confidential information of each Party may be disclosed to
the other Party in connection with this Agreement. Each Party receiving such non-public, proprietary, or confidential information
(the “Receiving Party”) agrees that it will take steps at least substantially equivalent to the steps it takes
to protect its own non-public, proprietary, or confidential information (but in no event less than reasonable care), during the
term of this Agreement and for a period of there (3) years following expiration or termination of this Agreement, to retain
in confidence the terms of this Agreement and all other non-public, proprietary or confidential information, technology, materials
and know-how of the other Party disclosed or acquired by the Receiving Party pursuant to or in connection with this Agreement(“Confidential
Information”).

 

    		Page 9 of 17	 

     
G MEDICAL Distribution Agreement Proprietary and Confidential

    

 

15.2 Except as permitted herein, each Party
agrees to hold in confidence, not to disclose, to prevent the disclosure of Confidential Information of the other Party and to
refrain from copying, distributing, disseminating or otherwise disclosing such Confidential Information to, any third party; provided
that each Party may disclose Confidential Information to its directors, officers, employees advisors or agents who (i) need to
have access to such Confidential Information for such Party to perform its obligations hereunder and (ii) will agree to treat Confidential
Information in the same manner and to the same extent as is required of the Receiving Party hereunder. The provisions of this Section
15.2 above shall not relieve the Receiving Party from its obligations hereunder, and any breach of this Agreement by Receiving
Party’s directors, officers, etc., shall be deemed as a breach of this Agreement by Receiving Party. Each Party shall notify
the other Party promptly in writing in the event such Party learns of any actual or suspected unauthorized use or disclosure of
any Confidential Information that it has received from the other Party, and will cooperate in good faith to remedy such unauthorized
use or disclosure to the extent reasonably possible.

 

15.3 The Receiving Party undertakes not
to use the Confidential Information of the Disclosing Party for any purposes other than for the purposes of performing this Agreement,
and not to sell, grant, make available to, or otherwise allow the use of the Disclosing Party’s Confidential Information
by any third party, directly or indirectly, except as expressly permitted herein.

 

15.4 Without derogating from the generality
of the above, Distributor undertakes not to use, directly or indirectly, the Confidential Information of G MEDICAL in the development
and/or sale of products having the same or similar functions as the Products, for itself or for a third party.

 

15.5 All Confidential Information shall
be and remain the property of the Disclosing Party. Disclosure of the Disclosing Party’s Confidential Information to the
Receiving Party shall not be construed as granting the Receiving Party any right, title, or license, whether express or implied,
with respect to the Confidential Information or to its related Intellectual Property or products (including, but not limited to,
improvements, modifications and/or derivatives related to the Confidential Information), other than the right to use the Confidential
Information strictly in accordance with the provisions of this Agreement and the relevant Purchase Order. The right to file property
rights based on the Confidential Information shall be reserved to the Disclosing Party. The Receiving Party shall not assert a
right based on prior use, or assert an objection of public prior use, against property rights based on Confidential Information
received under this Agreement.

 

15.6 The restrictions hereunder with respect
to Confidential Information shall not apply to any information that: (i) was known by the Receiving Party without obligation of
confidentiality prior to disclosure thereof by the other Party due to no wrong doing of the Receiving Party, as can be substantiated
by written and dated records; (ii) was in or entered the public domain through no breach by the Receiving Party of its obligation
with respect to Confidential Information; (iii) is disclosed to the Receiving Party by a third party legally entitled to make
such disclosure without violation of any obligation of confidentiality; (iv) is independently developed by the Receiving Party
without use or reference to any Confidential Information of the other Party, as can be substantiated by written and dated records;
or (v) is expressly released in writing from such obligations by the Disclosing Party.

 

15.7 Disclosing Party’s Confidential
Information is provided on an “as is” basis, with no warranty, express or implied, regarding the accuracy and/or
completeness thereof.

 

Upon (I) the written request of the Disclosing
Party, or (ii) expiration or termination for any reason of this Agreement or the applicable Purchase Order (to the extent related
to the Confidential Information), the Receiving Party shall return to the other or destroy (as requested by the Disclosing Party
at its sole discretion), all materials, in any medium, which contain or reveal all or any part of any Confidential Information
of the Disclosing Party. The Receiving Party shall confirm such destruction or return in writing to the Disclosing Party.

 

    		Page 10 of 17	 

     
G MEDICAL Distribution Agreement Proprietary and Confidential

    

 

Each Party
acknowledges that breach of its obligation with respect to Confidential Information as provided by this Section 15 may result in
extensive and irreparable harm and damage to the other Party, for which money damages would be an insufficient remedy, and therefore
the non-breaching Party shall be entitled to seek injunctive relief to enforce the provisions of this Agreement with respect to
Confidential Information, in addition to any other remedy available to the other Party under applicable law. In such event, the
Party seeking injunctive relief to prevent use or disclosure of its Confidential Information as above, shall not be bound by the
escalation procedure set out in Section 16.16 below

 

15.8 Notwithstanding
anything to the contrary contained elsewhere in this Agreement, either Party may issue a disclosure containing Confidential Information
of the other Party without the consent of the other Party to the extent such disclosure is required by law, rule, regulation, judicial
or administrative order, or government or court order or evidenced by a subpoena, or is requested by a governmental or other entity
authorized by law to make such request (including, without limitation, a stock exchange where Receiving Party's stocks are listed
for public trading); provided, however, that, to the extent reasonably practicable, the disclosing Party will provide prompt prior
written notice to the other Party and will reasonably cooperate with the other Party (at the Disclosing Party's expense), if it
seeks a protective order or takes other legal action to prevent the disclosure of such Confidential Information (unless the disclosing
Party is prohibited by law from so doing), and, provided further, that the disclosure shall be limited to the extent expressly
required.

 

15.9 The
provisions of this Section 15 shall survive any expiration or termination of this Agreement and shall remain in effect and binding
upon the Parties following the date of such expiration or termination, as the case may be.

 

 16. GENERAL PROVISIONS

 

16.1 Notices.
Any and all notices which either Party may desire to give the other Party must be in writing and may be given by (i) personal delivery
to an officer of the Party, (ii) by mailing the same by registered or certified mail, postage prepaid, return receipt requested,
or via internationally recognized courier services to the Party at the address of such Party as set forth in the heading of this
Agreement, or such other address as the Parties may hereinafter designate. Such notice or other communications shall be deemed
to have been given on the date confirmed as the actual date of delivery by the courier service if sent by such service.

 

16.2 Governing Law and
Jurisdiction. Any controversy or claim arising out of or relating to this Agreement, or the breach thereof, shall be
governed, construed and interpreted in accordance with the laws of England and Wales ,
exclusive of conflict or choice of law rules. This Agreement shall not be governed by the United Nations Convention on the
International Sale of Goods. G MEDICAL and Distributor will attempt to settle any claim or controversy arising out of this
Agreement through consultation and negotiation in good faith and spirit of mutual cooperation. Disputes will be resolved by
the following process. The dispute will be submitted in writing to a panel of two (2) senior executives, one from each of G
MEDICAL and Distributor for resolution. If the executives are unable to resolve the dispute within fifteen (15) days, either
Party may refer the dispute to mediation, the cost of which will be shared equally by the Parties, except that each Party
will pay its own attorney's fees. Within fifteen (15) days after written notice demanding mediation, the Parties will choose
a mutually acceptable mediator. Neither Party will unreasonably withhold consent to the selection of the mediator. Mediation
shall be conducted in London, England (UK) . If the dispute cannot be resolved through mediation within forty-five (45) days,
either Party may submit the dispute to arbitration pursuant to the Commercial Arbitration Rules of the UK Arbitration
Association. All proceedings shall take place before a single arbitrator in London City.

 

16.3 Compliance.
Each Party agrees to and shall comply with all applicable provincial, federal, and where applicable, local rules

and regulations.

 

    		Page 11 of 17	 

     
G MEDICAL Distribution Agreement Proprietary and Confidential

    

 

16.4
Indemnification. Distributor will indemnify, defend and hold harmless G MEDICAL, and its officers, directors, employees
and agents thereof (hereinafter referred to as the "G MEDICAL Indemnitees") from and against any and all claims,
demands, suits, actions, liabilities, judgments, losses, deficiencies, damages and expenses (including reasonable attorneys’
fees), incurred in investigating and defending against any claims, actions or liabilities asserted against or suffered by G MEDICAL
and/or G MEDICAL's Indemnitees arising out of or in connection with (i) any services and related activities by Distributor or
its employees or agents pursuant to this Agreement; (ii) the violation by Distributor of any of the obligations under this Agreement
or under any applicable law, rule or regulation, or (iii) any of Distributor's representations in Section 13 above being inaccurate
or false. G MEDICAL shall give prompt written notice to Distributor after learning of any such claim, action or liability for
which indemnification is provided herein, but the failure to give such notice shall not release Distributor from its indemnification
obligations hereunder.

 

16.5 LIMITATION
OF LIABILITY. TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, IN NO EVENT SHALL G MEDICAL BE LIABLE TO THE DISTRIBUTOR OR
ANY THIRD PARTY FOR (I) ANY INCIDENTAL, INDIRECT, SPECIAL, PUNITIVE OR CONSEQUENTIAL DAMAGES, (II) ANY DAMAGES RESULTING FROM LOSS
OF REVENUES, LOSS OF PROFITS, LOSS OF GOODWILL OR LOSS OF USE, AND/OR (III) ANY THIRD PARTY CLAIMS AGAINST DISTRIBUTOR; ARISING
OUT OF, OR IN CONNECTION WITH, THIS AGREEMENT AND/OR ANY PRODUCTS OR PURCHASE ORDER, REGARDLESS OF THE BASIS FOR LIABILITY OF ANY
CLAIM (BE IT CONTRACT, TORT, OR OTHERWISE), EVEN IF G MEDICAL WAS INFORMED OF THE POSSIBILITY OF SUCH DAMAGES.

 

G MEDICAL’S MAXIMUM CUMULATIVE
LIABILITY TO DISTRIBUTOR UNDER THIS AGREEMENT AND/OR ANY PURCHASE ORDER, SHALL NOT EXCEED THE AMOUNT RECEIVED BY G MEDICAL FROM
DISTRIBUTOR FOR THE APPLICABLE PURCHASE ORDER THAT IS THE SUBJECT OF THE DISPUTE.

 

THE ABOVE LIMITATIONS OF LIABILITY
SHALL ALSO APPLY TO THE BENEFIT OF G MEDICAL’S DIRECTORS, EMPLOYEES, AGENTS AND SUBCONTRACTORS.

 

16.6
Insurance. Distributor shall maintain products liability and such other insurance coverage as G MEDICAL
may reasonably require from time to time containing such terms and policy limits as G MEDICAL may reasonably require. Upon request,
Distributor shall deliver a certificate of insurance demonstrating existent coverage.

 

16.7 Export.
Distributor agrees to comply with the applicable export and import control laws, regulations and requirements in all countries
where Distributor shall resell the Products, and G MEDICAL assumes no responsibility or liability for Distributor's failure to
obtain any such necessary export and import approvals.

 

Without derogating form the generality
of the above, Distributor agrees to comply with all applicable laws and regulations which may govern the export of the Products,
including without limitation, the Export Administration Act of 1979, as amended, any successor legislation and the Export Administration
Regulations issued by the Department of Commerce. Distributor hereby gives its assurance that neither Products, parts, software,
or technical data provided by G MEDICAL under this Agreement are intended to be shipped, directly or indirectly, to prohibited
countries or nationals thereof.

 

16.8 Media
Releases. Except for any announcement intended solely for internal distribution or any disclosure required by legal, accounting,
or regulatory requirements, all media releases, public announcements, or public disclosures, including but not limited to promotional
or marketing material, by Distributor or its employees or agents relating to this Agreement or its subject matter, or including
the Marks of G MEDICAL, shall be coordinated with and approved in writing by G MEDICAL prior to the release thereof.

 

16.9 Section
Headings. Section headings in this Agreement are for convenience only, and shall not be used in construing the Agreement.

 

16.10 Incorporation
of all Exhibits. Each Exhibit (as defined below) referred to and attached hereto is incorporated by reference as if set forth
fully herein.

 

    		Page 12 of 17	 

     
G MEDICAL Distribution Agreement Proprietary and Confidential

    

 

16.11 Severability.
If any provision of these terms and conditions shall be held to be invalid, illegal or unenforceable, such provision shall be enforced
to the fullest extent permitted by applicable law and the validity, legality and enforceability of the remaining provisions shall
not in any way be affected or impaired thereby.

 

16.12 No
Implied Waivers. If either Party fails to require performance of any duty hereunder by the other Party, such failure shall
not affect its right to require performance of that or any other duty thereafter. The waiver by either Party of a breach of any
provision of this Agreement shall not be a waiver of the provision itself or a waiver of any breach thereafter, or a waiver of
any other provision herein.

 

16.13 Amendment.
This Agreement shall not be amended without the express prior written consent of both Parties hereto. Any amendment affected in
accordance with this Section 16.13 shall be binding upon all Parties hereto.

 

16.14 Assignment.
None of Distributor’s rights created nor obligations imposed hereunder or under and Purchase Order shall be assigned, subcontracted
or otherwise transferred to any other person or company, whether by operation of law or otherwise without G MEDICAL’s prior
written approval. Any purported assignment without such prior written approval shall be null and void, shall not be binding upon
G MEDICAL and shall not relieve Distributor from any liability or obligation under this Agreement. Subject to the foregoing, this
Agreement shall be binding upon and shall inure to the benefit of the Parties hereto and their respective successors and permitted
assigns.

 

16.15 Entirety.
This Agreement, together with its Exhibits, constitutes the entire agreement between the Parties regarding its subject matter.
This Agreement supersedes any and all previous proposals, representations or statements, oral or written. Any previous agreements
between the Parties pertaining to the subject matter of this Agreement are expressly terminated. Any modifications or amendments
to this Agreement must be in writing and signed by authorized representatives of both Parties. In the event of any inconsistency
or contradiction between the provisions of this Agreement and the provisions of an Exhibit or a Purchase Order, the provisions
of this Agreement will prevail with respect to the subject matter of such inconsistency or discrepancy.

 

16.16 Force
Majeure. A Party hereto shall not be liable for any delay, loss and/or damage resulting from causes beyond the control thereof,
including, but not limited to, acts of God, acts of a public enemy, acts of any governmental or quasi-governmental agency or any
of their political subdivisions, fire, flood, epidemics, explosion, power or telecommunications irregularities, quarantine restrictions;
strikes or other labor unrest, earthquakes, civil commotion or revolutions, war, terrorist attack, freight embargoes, unusually
severe weather conditions, or any other cause that was not reasonably foreseeable by such Party on the date of signing of this
Agreement or the relevant Purchase Order.

 

16.17 No
Solicitation. During the term of this Agreement and for a period of six (6) months from the expiration or termination thereof
for any reason, neither Party shall (i) solicit to hire or otherwise employ any of the executive officers, technical personnel
and/or other employees of the other Party or of the other Party's subcontractors, except by the prior written consent of the other
Party, nor (ii) solicit suppliers and/or customers of the other Party to cease their cooperation therewith. Solely for purposes
of this Section 16.19, the other Party's independent contractors shall be deemed as such Party's employees.

 

16.18 No
Third Party Beneficiaries. This Agreement does not create any obligation of a Party to any third parties, nor shall it be deemed
to create any rights or causes of action on behalf of any third parties.

 

16.19 Remedies.
All remedies, either under this Agreement or by law otherwise affording to any Party, shall be cumulative and not alternative

 

16.20 Counterparts.
This Agreement may be executed in two (2) or more counterparts, each of which will be considered an original, but all of which
together will constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise)
by facsimile or electronic transmission shall be sufficient to bind the Parties to the terms and conditions of this Agreement.

 

16.21 Language.
The Parties hereto have requested that this Agreement and all correspondence and all documentation relating to

this Agreement,
be written in the English language.

 

[remainder of page intentionally
left blank; signature page follows]

 

    		Page 13 of 17	 

     
G MEDICAL Distribution Agreement Proprietary and Confidential

    

 

IN WITNESS WHEREOF, G MEDICAL
and Distributor have caused this Agreement to be executed by their duly authorized representatives, each of which shall constitute
an original as of the Effective Date.

  

	 	 	 
	G Medical Innovations Ltd	 	 

  

	By:	/s/ Brendan de
    Kauwe	 	By:	/s/ Graham Russell
	Printed Name:  Brendan
    de Kauwe	 	Printed Name:  Graham Russell
	Title:	Director	 	Title:	Managing Director
	Date:	21/4/20	 	Date:	22 April 2020

 

	 	By:	/s/ Melanie Ross
	 	Printed Name: Melanie Ross              
	 	Title: 	 Company Secretary
	 	Date:	 22 April 2020

   

    		Page 14 of 17	 

     
G MEDICAL Distribution Agreement Proprietary and Confidential

    

 

EXHIBIT A

 

PRODUCTS and PRODUCT TERMS

 

		1.	PRODUCTS

 

		a.	Product 1

 

		·	Prizma G2 with User portal

 

		1.	API for transfer data to Australian third-party cloud.
	 	 	 

		2.	Launching of Prizma APP from another HSC application.
	 	 	 

		3.	Integration of Prizma APP into HSC portal

 

    		Page 15 of 17	 

     
G MEDICAL Distribution Agreement Proprietary and Confidential

    

 

EXHIBIT B

 

TERRITORIES

 

Distributor may resell and distribute the Products
only in:

 

		1.	Australia (non-exclusive)

 

		2.	New Zealand (non-exclusive)

 

    		Page 16 of 17	 

     
G MEDICAL Distribution Agreement Proprietary and Confidential

    

 

EXHIBIT C

 

PRODUCT FORECAST & PRICE LIST

 

FORECAST (MOQ) – in accordance to para
3.1. :

 

PRIZMA:

 

		1.	20 units (Prizma G2) initial order, thereafter units may
be ordered as required.

 

PRICE LIST:

 

PRIZMA:

 

		1.	Distributor price: $150 per unit (Prizma G2).
	 	 	 

		2.	Retail (consumer) Price: $249.
	 	 	 

		3.	Prizma Portal fee of no less than $9 per month.
	 	 	 

		(a)	Portal fee of 30% payable to Distributor.
	 	 	 

		(b)	Additional service fees to be agreed between G Medical
and Distributor.

 

 

    		Page 17 of 17Exhibit 10.23

 

Certain
confidential information contained in this document, marked by brackets and asterisk, has been omitted pursuant to Item 601(b)(10)(iv)
of Regulation S-K, because it (i) is not material and (ii) would be competitively harmful if publicly disclosed

 

Media
and Marketing Services Agreement

 

This
MEDIA AND MARKETING SERVICES AGREEMENT (“Agreement”) is made and entered into as of September 30, 2020 (the
“Effective Date”) by and between G MEDICAL INNOVATIONS HOLDINGS LTD., a Cayman Islands exempted company (“Company”),
and GRS, LLC, a Delaware limited liability company (“GRS”). GRS and Company may each be referred to herein
as a “Party” and, collectively, as the “Parties.”

 

WHEREAS,
Company is in the business of developing, marketing, selling and distributing the Company Consumer Products (as defined below);

 

WHEREAS,
GRS has expertise in advising companies in the development and implementation of direct response media campaigns, including
radio and television direct response commercials, to promote various products and services, and in the purchasing of media time
in connection with the foregoing; and

 

WHEREAS,
Company desires to receive from GRS, and GRS desires to provide to Company, certain media purchasing, production, advertising
and marketing services in connection with the advertising and marketing of Company Consumer Products, in the United States (the
“Territory”), on the terms and conditions set forth herein.

 

NOW
THEREFORE, in consideration of the foregoing premises and the respective agreements, covenants, representations, warranties
and conditions herein contained, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,
the Parties, intending to be legally bound, hereby agree as follows:

 

1. Products;
Services; Responsibilities of Parties.

 

1.1
 GRS Services. During the Term (as defined below), GRS shall provide the following
services (collectively, “GRS Services”) in connection with the advertising and marketing of Company Consumer
Products in the Territory:

 

(i)
Manage and purchase media time on Company’s behalf for airing of television, radio, social media and Internet advertising
of Company Consumer Products and any other Company consumer service, in each case as reasonably determined by GRS in consultation
with Company, and in accordance with the terms of this Agreement, including the budget requirements set forth in Section 2.1
below (collectively with the services set forth in Section 1.1(ii) and 1.1(iii), the “Media Campaign”).
GRS may collect or retain a standard media commission on all media booked by GRS on behalf of Company, not to exceed [**]%.

 

(ii)
Subject to Section 1.3(iv) below, create, develop and/or produce (or cause a third party reasonably acceptable to Company
to create, develop, and/or produce) (a) television, social media and radio commercials, and (b) other creative content that are
pre-approved by Company for use in the Media Campaign (collectively, “Content”), in connection with the advertisement,
marketing, and promotion of Company Consumer Products. Content shall be delivered to Company by GRS for Company’s review
and approval in accordance with a schedule mutually agreed to by both Parties.

 

     

     

    

 

(iii) Report
to Company on a weekly basis (or as otherwise agreed by the Parties) information which is reasonably available to GRS regarding
media purchased or committed to be purchased pursuant to Section 1.1(i) during the prior week in reasonable detail, including
the dollar amounts committed to in such purchases, which media is to be aired, the dates the media is scheduled to be aired and
where the media is scheduled to be aired, and provide such other reports as mutually agreed to by the Parties.

 

(iv) Meet
with Company regularly to discuss Company initiatives and priorities in the Territory.

 

(v) Provide
such other production, advertisement and marketing services as agreed to by the Parties in writing from time to time during the
Term.

 

As
used in this Agreement, “Company Consumer Products” means all products developed by Company and Affiliates (as defined
below) or on the Company’s behalf, including, without limitation, the Prizma mobile medical monitor.

 

		1.2	Company’s
                                         Responsibilities. During the Term, Company shall:

 

(i) In
addition to the issuance of the Warrant (defined in Section 3 below), Company shall:

 

(a) Pay
to GRS in cash or cash equivalents, in consideration of the GRS Services, the following amounts:

 

i. A
monthly marketing fee in an amount equal to [**] USD ($[**]) (the “Monthly Retainer”). [**] USD ($[**]) of
the Monthly Retainer shall be due in advance on or prior to the first of each month. The remaining [**] USD ($[**]) of the Monthly
Retainer shall be deferred until completion of the Company’s planned NASDAQ Initial Public Offering (the “IPO”),
at which time as such deferred amounts shall become immediately due and payable. Commencing with the month after an IPO is completed,
the entire Monthly Retainer shall be due in advance on or prior to the first of each month.

 

ii. A
commission (the “Commission”) equal to [**] Percent ([**]%) of gross revenues actually collected by, or credited
to, the Company or its Affiliates (if any), from the sale of Company Consumer Products in the Territory during the Term, excluding
revenue generated from or in connection with the Company’s Independent Diagnostic Testing Facility (collectively, “Gross
Revenue”), due in arrears within ten (10) days following the end of an applicable month. In the event that in any month
Company shall be required to pay GRS a Commission in excess of $[**], then the full Monthly Retainer amount shall be waived for
such month, and any amounts previously paid for the Monthly Retainer in such month shall be credited against the amount of the
Commission which is due.

 

    2

     

    

 

(b) At
such time as Company shall be required to pay GRS the Commission, Company shall provide GRS a report of its calculation of Gross
Revenue and the Commission for the applicable month (each, a “Commission Statement”). Company will maintain
books and records relevant to the determination of Gross Revenue hereunder for a period of no less than two (2) years following
the expiration or termination of this Agreement. Upon GRS’s written request within twelve (12) months after receipt of a
Commission Statement, Company agrees to provide reasonable supporting documentation concerning such Commission Statement or Commission
Statements within thirty (30) days of such written request. Further, Company will permit GRS, or an independent Certified Public
Accountant designated by GRS, to make an examination, at GRS’s expense (except as provided below), of the books and records
applicable to such Commission Statement(s) and/or the calculation of the Gross Revenue within eighteen (18) months after receipt
of a Commission Statement, which examination may take place upon thirty days advance written notice to Company, at Company’s
office (or such other place as designated by Company) during reasonable business hours and not more than one (1) time every twelve
months. The examination may relate only to the calculation of the Commission payable to GRS during the relevant period. In the
event that an examination uncovers an underpayment to GRS of 3% or more annually, Company shall be responsible for all reasonable
fees of GRS of such examination. GRS’s audit rights pursuant to this Section 2.5 shall survive the termination of this Agreement
for two (2) years following the effective date of termination.

 

(c) Reimburse
GRS for reasonable expenses incurred in connection with GRS’s performance of the GRS Services under this Agreement, provided
that monthly expenses exceeding $2,000 in the aggregate and any single expense in excess of $500 shall be subject to Company’s
pre-approval in writing.

 

(ii) Company
shall pre-pay GRS for development, preproduction, production, post-production, media time and other related expenses incurred
in connection with the Content as set forth in each Approved Creative Budget (as defined below) and pursuant to Sections
1.3(iv) and 2 below, respectively. It is the Parties’
intention that at no time will GRS guarantee, finance, or otherwise be obligated to pre-pay any of Company’s media or production
spends (i.e., Company will pay GRS in advance for all third-party production and media related expenses/costs as set forth
in Sections 1.3(iv) and 2 below, respectively).

 

(iii) License
to GRS the right to use Company Marks (as defined below) in accordance with the terms and conditions of Section 7.3 below
solely in connection with GRS’s provision of the GRS Services.

 

(iv) Deliver
to GRS, or grant access to GRS or its representatives to review and copy, via an internet-based interface and/or other format
mutually acceptable to the Parties, reasonably detailed periodic reports (in such time periods as mutually agreed to by the Parties,
but in no event less than weekly) which set forth all information reasonably requested by GRS in order to evaluate the success
of any particular media and/or Content which is included in the Media Campaign (“Media Report”), and which
reflect the cumulative gross sales of Company Consumer Products in the Territory during the Term (“Sales Report”).
The Parties acknowledge that GRS’s ability to perform the GRS Services in a timely and effective manner is contingent upon
GRS’s timely receipt of the Media Report and such unique visitor and viewer data, conversion detail and ongoing optimization
efforts which are reasonably available to Company.

 

(v) Be
responsible for all aspects of running the day-to-day business of Company in connection with the advertisement, marketing and
provision of Company Consumer Products (other than those aspects covered by the GRS Services), including managing and operating
all inbound call centers, product fulfillment, customer services, and all other aspects of the day to day operations of Company’s
business.

 

    3

     

    

 

(vi) Promptly
notify the GRS Representative (as such term is hereinafter defined) of any inquiries or notices received by Company or any of
its employees, agents or representatives from any governmental entity or agency, state attorney general or governmental investigative
body, or of any notices of actual third party suits or claims, relating to or relevant and material to the Media Campaign, the
GRS Services or Company Consumer Products, and deliver a copy of any written correspondence relating thereto, or a summary of
any oral inquiry or notice, to the GRS Representative no later than five (5) business days following Company’s receipt of
such correspondence or inquiry.

 

		1.3	Other
                                         Provisions Affecting GRS Services.

 

(i) GRS
shall designate one (1) representative reasonably acceptable to Company who shall serve as the primary point of contact for Company
in dealing with GRS in matters referring or relating to the GRS Services (the “GRS Representative”). The GRS
Representative shall be available to Company during GRS’s normal business hours. The GRS Representative shall be Boris Shimanovsky
(“Shimanovsky”). So long as Shimanovsky is employed by GRS or any of its Affiliates (as such term is hereinafter
defined) and subject to the reasonable professional availability of Shimanovsky, GRS shall cause Shimanovsky to provide creative
advisory services to Company in connection with the provision of the GRS Services.

 

(ii) Company
shall designate one (1) representative reasonably acceptable to GRS who shall serve as the primary point of contact for GRS in
dealing with Company in matters referring or relating to the GRS Services (“Company Representative”). The Company
Representative shall be responsible for delivering all consents or approvals by authorized Company officers and making all requests
on behalf of Company. The initial Company Representative shall be Yacov Geva.

 

(iii) GRS
shall manage the day-to-day creation, development and production of the Content; provided, however, that Company shall have final
approval over all Content, as well as any third parties to be engaged by GRS to perform the GRS Services.

 

(iv) The
Parties shall mutually agree on the applicable budget(s) for the development and production of the Content (each, an “Approved
Creative Budget”), and Company shall be obligated to pre-pay GRS, on a monthly basis, for all production/creative expenses
to be incurred by GRS as set forth in each Approved Creative Budget. No later than thirty (30) days from the Effective Date, the
Parties shall: (A) establish a written Approved Creative Budget for the remainder of calendar year 2020, and (B) agree on a process
for establishing Monthly Media Budgets (defined below) for the remainder of calendar year 2020 and all future years of the Term
pursuant to Section 2.1. Until Company provides its approval to the content and other creative aspects and budget for particular
Content and has advanced to GRS all production/creative expenses to be incurred in connection with such Content, GRS shall have
no obligation to produce, revise, edit and/or otherwise modify, as the case may be, such Content and/or manage and purchase media
time for such Content.

 

2. Media
Placement Costs; Payment Obligations.

 

2.1 Budgeted
Media Placement Costs. Not later than fifteen (15) days prior to the beginning of each month, Company shall deliver to GRS
a budget prepared in good faith in consultation with GRS, and in accordance with Section 1.3(iv), which sets forth the
aggregate minimum and maximum dollar amount that GRS shall expend on media placement (“Media Placement Costs”)
for radio, television and digital/social advertising for the following month (“Monthly Media Budget”). GRS
shall use commercially reasonable efforts to ensure that its agreement with each media seller provides at the minimum that the
media seller shall provide credits or refunds to GRS for any media purchased but not run or any media that is run incorrectly.
GRS shall cause an amount equal to any credits or refunds received by GRS from any media seller to be credited against any amounts
owing by Company to GRS for Media Placement Costs pursuant to Section 2.2 hereof.

 

    4

     

    

 

2.2 Payment
of Media Costs. Company shall pay GRS in advance for media costs reflected in the Monthly Media Budget at least fourteen (14)
days prior to the air date(s) for the applicable month. GRS shall directly pay all Media Placement Costs to third parties (subject
to reimbursement from Company as provided below). GRS shall deliver to Company monthly invoices which set forth in reasonable
detail the amount of all actual Media Placement Costs paid by GRS to third parties in connection with providing the GRS Services
during such month. Company shall pay all such invoiced amounts within five (5) days after Company’s receipt of GRS’s
invoice. GRS shall cause any pre-paid Media Placement Costs paid by Company for an applicable month but that are not actually
spent by GRS in such month to be credited against any amounts owing by Company to GRS for Media Placement Costs in the following
month, provided that if this Agreement terminates prior to such month, then GRS shall refund such unspent amounts back to Company.
All costs incurred by GRS in connection with third-party talent engagements shall be passed through to Company without markup.

 

3. Issuance
of Warrant. The Parties acknowledge and agree that no later than five days after the Company’s IPO, in consideration
of the services to be provided by GRS herein, Company shall issue to GRS a warrant (in the form of the Warrant attached hereto
as Exhibit A (the “Warrant”) to purchase up to that number of shares of Company’s Common Stock equal
to 5% of the Company’s outstanding Common Stock (calculated on a fully diluted, as converted basis) as of the issuance date
of the Warrant (the “Warrant Shares”). Fifty Percent (50%) of the Warrant (the “Initial Tranche”)
shall vest retroactively upon execution of the Deal Memo entered into between the Parties dated September 18, 2020 (the “Deal
Memo”) and the remaining Fifty Percent (50%) (the “Second Tranche”) shall vest on September 18, 2021,
unless, solely with respect to the Second Tranche, the Agreement has been terminated pursuant to Section 5.2 prior to such date.
The Warrant shall be exercisable for a period of nine (9) years from the date of issuance (including by way of cashless exercise).
The initial traunch of the Warrant shall have an exercise price equal to Five Cents AUD (AUD 0.05) per Warrant Share (subject
to adjustment on the terms and conditions set forth in the Warrant). The second traunch of the Warrant shall have an exercise
price equal to the lessor of a Fifty Percent (50%) discount to the IPO price or a Fifty Percent (50%) discount to the Company’s
share price on the date of vesting. Without limiation to the provisions of Section 6 below, the Initial Tranche shall be subject
to a customary “market stand-off agreement” in connection with the Company’s IPO that contains a lock-up period
identical to the period applicable to non-affilaite shareholders of the Company, but not more than six (6) months from the date
the Company’s IPO. The Company shall cause the Warrant Shares to be included in the Form F-1 registration statement (or
any similar registration statement) that the Company files in connection with the Company’s IPO.

 

4. Exclusivity.
During the Term, GRS shall be the exclusive provider for Company of all direct response television, radio, social media and Internet
media purchasing and production services comprising the GRS Services in the Territory, and Company shall not carry out such services,
directly or indirectly, or obtain such services from any other party in the Territory without the prior written consent of GRS,
which may be withheld by GRS in its sole discretion.

 

    5

     

    

 

5. Term/Termination;
Breach of Payment Obligations.

 

5.1
 Term. Subject to any termination rights set forth herein, the term (“Term”)
of this Agreement shall commence on the Effective Date and continue for a period of thirty six (36) months thereafter, unless
earlier terminated in accordance with the provisions of this Agreement. Renewal of the Term shall only be effective upon mutual
written agreement by both Parties.

 

5.2 Termination.
This Agreement may be terminated prior to the end of the Term under the following circumstances and as provided elsewhere
herein:

 

(i) by
a Party if the other Party breaches any material provision of this Agreement or defaults in the performance of any material obligation
hereunder, unless such breach or default is cured within thirty (30) days following receipt of written notice thereof from the
non-breaching Party.

(ii) immediately
by either Party upon (a) the discontinuance, dissolution, liquidation and/or winding up of the other Party’s business or
(b) the making, by the other Party, of any general assignment or arrangement for the benefit of creditors; the filing by or against
the other Party of a petition to have it adjudged bankrupt under bankruptcy or insolvency laws, unless such petition shall be
dismissed or discharged within sixty (60) days; the appointment of a trustee or receiver to take possession of all or substantially
all of such Party’s assets, where possession is not restored to the appropriate party within thirty (30) days; or the attachment,
execution or judicial seizure of all or substantially all of the other Party’s assets where attachment, execution or judicial
seizure is not discharged within thirty (30) days.

 

5.3 Effect
of Termination. Upon the expiration or earlier termination of this Agreement as provided in Section 5.2 above:

 

(i)
GRS shall immediately cease purchasing any additional media time on Company’s behalf and take commercially reasonable
and appropriate action to cease all third-party work in connection with the GRS Services.

 

(ii)
 In the event of the termination of this Agreement by GRS pursuant to Sections 5.2(i)
or (ii) above, or by Company for any reason other than as set forth in Sections 5.2(i), or (ii) above, within twelve months from
the Effective Date of this Agreement, Company shall not, for a period of twelve (12) months following the effective date of such
termination, itself or through its Affiliates, directly or indirectly, acquire any television, digital or radio media time, engage
in any paid television, digital or radio advertising (including any shared advertising) or create, develop and/or produce television,
digital or radio commercials, in each case relating to Company Consumer Products (the “Advertising Restriction”),
without the prior written consent of GRS, which GRS may withhold in its sole discretion, unless Company elects to accelerate the
vesting of any Unvested Shares (as defined in the Warrant), in which case Company’s post-Term activities shall not be subject
to the Advertising Restriction. Should Company violate the Advertising Restriction, all Unvested Shares shall automatically vest.

 

(iii) Upon
the applicable Party’s written request, each Party shall return or destroy (with a certificate of destruction to the other
Party, if such other Party so requests) any Confidential Information of the other Party in its possession or control.

 

5.4 Survival.
Sections 1.4, 3, 5.3, 6, 7, 8.2(iv), 8.2(v), 10 through 13, and 15 through 25
shall survive termination or expiration of this Agreement.

 

    6

     

    

 

6.
 Confidentiality.

 

(i) Each
Party may disclose to the other certain confidential or proprietary information in connection with the performance of this Agreement,
including marketing proposals and plans, creative designs and concepts, trade secrets and know-how, customer lists, software,
business plans, forecasts, financial documents, customer information, and other information which the disclosing Party has designated
as “Confidential,” “Proprietary,” or some similar designation. or which the receiving Party reasonably
should know is otherwise subject to an expectation of privacy, and which when provided hereunder, should be treated as confidential
(collectively, “Confidential Information”). The terms of this Agreement shall be considered Confidential Information.
Each Party shall use the Confidential Information of the other solely to perform this Agreement, and all Confidential Information
shall remain the sole property of the Party disclosing such information. Each Party shall hold the Confidential Information in
strict confidence and shall not make any disclosure of the Confidential Information to anyone without the express written consent
of the other Party, except to employees, consultants, agents, independent contractors or other representatives to whom disclosure
is necessary to the performance of this Agreement and who have executed a confidentiality agreement with confidentiality provisions
equally protective as those set forth herein, or are otherwise bound by a similar duty of confidentiality. Each Party shall use
the same care as it uses to maintain the confidentiality of its Confidential Information of the same or similar nature, which
shall in no event be less than reasonable care and no less than the level of care required by any applicable law. Each Party acknowledges
that the remedy at law for any breach or threatened breach of the provisions of this Section 6 may be inadequate, and that
each Party, in addition to any other remedy available to it, shall be entitled to seek injunctive relief from a court of competent
jurisdiction. Neither Party shall have any obligation under this Agreement with respect to any Confidential Information disclosed
to it which the Party can demonstrate: (a) was already known to it at the time of its receipt hereunder (other than as a result
of prior disclosure by the other Party), (b) is or becomes generally available to the public other than by means of the Party’s
breach of its obligations under this Agreement or a third party’s breach of its confidentiality obligations, (c) is independently
obtained on a non-confidential basis from a third party whose disclosure violates no duty of confidentiality, or (d) is developed
independently by the receiving Party with use or reference of the other Party’s Confidential Information as evidenced by
appropriate records. A Party may disclose Confidential Information pursuant to applicable law or regulation or by operation of
law, provided that such Party will disclose only such information as is legally required, and provided further that the Party
(if the Company – to the extent practicable of permitted under applicable law) shall provide reasonable notice to the other
Party of such requirement and a reasonable opportunity to object to such disclosure. A Party’s obligation to maintain the
confidentiality of Confidential Information shall remain for so long as the information remains Confidential Information of the
other Party.

 

(ii)
GRS acknowledges that it may receive certain material non-public information (financial, commercial or other). GRS is aware (and
will so advise its representatives) that securities laws impose restrictions on trading in securities when in possession of such
information. GRS further acknowledges and agrees that using such information and utilizing it to its benefit may cause the Company
to be in violation of applicable securities laws. GRS undertakes that it and/or any of its affiliates, employees, representatives
or anyone on its behalf, shall not, directly or indirectly utilize such information in a way which may be considered ‘inside
trading’ or in any way which may be considered prohibited, restricted misappropriate or otherwise in violation of the securities
laws applicable to the Company.

 

    7

     

    

 

7.
 Ownership.

 

7.1 GRS
Property. GRS owns all right, title and interest in and to all of the intellectual property, technology, software, databases,
inventions, templates, processes, marketing strategies and techniques, trademarks, service marks and logos, concepts, information,
and materials that are (i) in existence and owned or controlled by GRS or its relevant Affiliate prior to the date of this Agreement,
or (ii) created, developed or acquired at any time thereafter by GRS or its Affiliates without reliance on the Company Property
or (iii) otherwise created, developed or acquired at any time by GRS or its Affiliates and for which the intellectual property
rights, information rights or other available legal protection vest in GRS or such Affiliate by applicable law or contract (the
foregoing in (i)-(iii) individually and collectively, “GRS Property”). GRS Property is GRS’s sole and
exclusive property and shall remain the property of GRS, and GRS shall retain all proprietary, intellectual property, and any
other rights therein. If the parties mutually agree to use GRS trademarks or copyrights, or other intellectual property rights
during the Term of this Agreement other than as contemplated by this Agreement, the Parties will enter into a separate limited
license for such use on terms and conditions acceptable to GRS.

 

7.2 Company
Property. Company owns all right, title and interest in and to all of the intellectual property, technology, software, databases,
inventions, templates, processes, marketing strategies and techniques, trademarks, service marks and logos, information and materials
that are (i) in existence and owned or controlled by Company or its relevant Affiliate prior to the date of this Agreement, or
(ii) created, developed or acquired at any time by Company or its Affiliates, but excluding GRS Property (the foregoing in (i)-(ii)
individually and collectively, “Company Property”). Company Property is Company’s sole and exclusive
property and shall remain the property of Company, and Company shall retain all proprietary, intellectual property and any other
rights therein, subject to the licenses granted herein.

 

7.3 Generic
Information.  Notwithstanding any provision contained herein to the contrary, each Party agrees that neither Party shall
own, and neither Party shall be restricted from using, any generic or general business information, software, processes, formulas,
formulations, manufacturing techniques, procedures, promotions, and other items used, created or developed by either Party or
any of its Affiliates during the term of and in connection with this Agreement to the extent any of the foregoing is in the public
domain (other than as a breach by a Party of its obligations under this Agreement) or are not otherwise subject to any intellectual
property protection under applicable law.

 

7.4
 New Company Property. Except as otherwise set forth in Section 5.3(ii), upon
the termination/expiration of this Agreement, Company and its Affiliates shall have an exclusive, perpetual, irrevocable, non-sublicensable
(except to Affiliates), non-transferable (except to a permitted assignee of Company’s rights under this Agreement), right
to use in any manner and for any purpose whatsoever the specific creative content and advertising and marketing materials (including
any slogans, ideas, plans, proposals, musical themes, marketing concepts, and other creative products), created and delivered
hereunder by GRS exclusively related to Company goods solely in connection with such goods, and all copyright, trademarks and
other intellectual property rights arising from or attaching to any advertising, marketing materials or other original works created
and delivered hereunder by GRS (individually and collectively, the “New Company Property”), subject in all
cases to any restrictions or other terms or conditions which are applicable to the ownership or use of any third party rights
which are included in such New Company Property and Company’s compliance with any terms or conditions relating to the use
of such third party rights. For clarity, New Company Property does not include, and GRS and its Affiliates shall not be precluded
from using, and Company shall have no right to use, the generic (i.e. not specific to Company services/goods) marketing
material templates, formats, processes, techniques, and media in which such New Company Property is embodied or delivered. GRS
agrees to use commercially reasonable efforts to deliver to Company, at its request, all layouts, artwork, engraving, films, tapes,
and other advertising materials comprising New Company Property which GRS shall have developed or made or caused to be developed
or made for Company.

 

    8

     

    

 

7.5 Limited
License. During the Term of this Agreement, Company grants GRS a non-exclusive, non-transferable (other than in connection
with a permitted assignment of this Agreement or to GRS Affiliates involved in the GRS Services), non-sublicensable, worldwide
royalty-free license to any Company Property provided or made available to GRS or a GRS Affiliate solely for the purpose of fulfilling
GRS’s obligations as set forth in this Agreement. To the extent that GRS creates any derivative works of Company Materials,
the Parties acknowledge and agree that such derivative works (excluding any GRS Property or Generic Materials and subject to Section
7.3) shall be owned by Company, and GRS hereby irrevocably assigns to Company, without additional consideration or restriction,
all worldwide right, title and interest in and to all such derivative works, and agrees that the assignment is effective as soon
as is possible under any applicable law, statue or regulation. It is understood and agreed that Company shall have no right to
use any of the GRS Property or New Company Property during the Term of the Agreement without GRS’s prior written consent.

 

7.6 Third
Party Work Product. GRS agrees that, in the case of any New Company Property created or produced by any person other than
GRS with whom GRS is contracting on behalf of Company under this Agreement, GRS will use commercially reasonable efforts to ensure
that, as between GRS and such person, ownership of all intellectual property rights attaching to such New Company Property is
vested in Company, provided that in cases where ownership of such New Company Property is not obtained despite GRS’s commercially
reasonable efforts, GRS will use commercially reasonable efforts to obtain a perpetual and exclusive right from such person to
use such New Company Property in favor of Company on equivalent terms as those provided in Section 7.4.

 

7.7
 General. All rights not specifically granted herein are reserved. Except as set
forth, each Party hereby acknowledges and agrees that it does not have and shall not acquire, any interest in any other Party’s
intellectual property except as provided in this Agreement and/or as may otherwise be expressly agreed to in writing executed
by both parties. For purposes of this Agreement, “intellectual property” means all intellectual property rights recognized
under any jurisdiction, including patents, copyrights, trademarks, trade names, and trade secrets.

 

7.8 Affiliate.
As used in this Agreement, an “Affiliate” means an individual, corporation, limited liability company, partnership,
trust, or other entity that directly or indirectly through one or more intermediaries, controls, or is controlled by, or is under
common control with, GRS or Company, as the case may be.

 

8.
 Representations, Warranties, and Covenants.

 

8.1 Both
Parties. Each Party represents and warrants to the other Party that: (a) it is duly organized, validly existing and in good
standing under the laws of its jurisdiction of incorporation or organization; (b) it has full power and authority to execute,
deliver and perform its obligations under this Agreement; and (c) this Agreement is a valid and binding obligation of such Party
and enforceable against such Party in accordance with its terms except as limited by applicable bankruptcy, insolvency, reorganization,
moratorium, fraudulent conveyance or other laws of general application relating to or affecting the enforcement of creditors’
rights generally.

 

    9

     

    

 

8.2 Company.
Company represents, warrants, covenants, and agrees, as follows:

 

(i)
 it has not entered into any oral or written contract or negotiations with any third
party which would impair the rights granted to GRS under this Agreement, or limit the effectiveness of this Agreement, nor is
it aware of any claims or actions which may limit or impair any of the rights granted to GRS hereunder;

 

(ii)
 all trademarks, logos, copyrights, materials, and work product related to Company or
otherwise used by Company in connection with the Media Campaign (which is not created or provided by GRS under this Agreement)
are owned by, and/or exclusively licensed to Company, and to the Company’s knowledge do not infringe or violate any United
States copyrights, trademarks, trade secrets, patents or other proprietary rights of any kind belonging to any third party or
violate any right of privacy, right to publicity, misappropriate anyone’s name or likeness or contain any defamatory, obscene
or illegal material;

 

(iii)
 it has received all necessary rights, clearances, licenses, and releases from third
parties regarding any materials provided by Company hereunder so that GRS may use such materials, in whole or in part, in connection
with the advertising, marketing and, promotion of Company Consumer Products, and in the publishing, airing and broadcast, as the
case may be, of the Content;

 

(iv)
 the issuance of the Warrant has been duly authorized by all requisite corporate action,
and Company has all requisite corporate power and authority to execute, deliver and perform its obligations under the Warrant;

 

(v) the
execution of this Agreement and the Warrant does not and will not conflict with or result in (A) a violation of any provision
of the charter or bylaws of Company or any law applicable to Company, or (B) a breach of Company’s obligations under, any
agreement, order, judgment or decree to which Company is a party or by which it is bound; and

 

(vi)
  it is now and will continue throughout the Term to be in full compliance with all local,
state, and federal laws, rules, and regulations applicable to its business and the advertising, marketing, and provision of Company
Consumer Products, including those of the Federal Consumer Fraud and Abuse Prevention Act, and the Federal Trade Commission, as
such may be amended from time to time, and any other state or federal regulatory agency that has jurisdiction over Company’s
business activities.

 

8.3 GRS.
GRS represents, warrants, covenants and agrees, as follows:

 

(i)
 it has not entered into any oral or written contract or negotiations with any third
party which would limit the effectiveness of this Agreement, nor is it aware of any claims or actions which may limit the effectiveness
of this Agreement;

 

    10

     

    

 

(ii)
 all trademarks, logos, and copyrights which are included with the GRS Property or GRS
Services (other than those provided by Company), and other related intellectual property rights used in the GRS Property or GRS
Services (other than those provided by Company) will be owned by, and/or exclusively licensed to (except as otherwise disclosed
to Company), GRS and to GRS’s knowledge will not infringe or violate any copyrights, trademarks, trade secrets, patents
or other proprietary rights of any kind belonging to any third party or violate any right of privacy, right to publicity, misappropriate
anyone’s name or likeness or contain any defamatory, obscene or illegal material; and

 

(iii) it
has received (or will receive) and paid for (or will pay for) all necessary rights, clearances, licenses, and releases from third
parties regarding the GRS Services and GRS Property (other than those related to Company Marks) so that GRS and Company may use
such materials in whole or in part, in connection with the advertising, marketing and, promotion of Company Consumer Products,
and in the publishing, airing and broadcast, as the case may be, of the Content.

 

9.
 Insurance.

 

9.1 Current
Insurance. Each Party shall obtain and maintain during the Term the following insurance coverage:

 

(i)
 Commercial General liability insurance with a limit of not less than $5 million per
claim/$5 million annual aggregate.

 

(ii) Errors
and Omissions/Professional Liability, including Media Liability insurance, with a limit of not less than $5 million per claim/$5
million annual aggregate.

 

(iii) Cyberliability
insurance with a limit of not less than $5 million per claim/$5 million annual aggregate.

 

9.2 Policy
Requirements. The insurance companies providing such insurance required under this Section 9 must have an A.M. Best
rating of A-VII or better and be licensed or authorized to conduct business in all 50 of the United States. Each Party shall name
the other Party as an additional insured on such insurance policies. Each Party shall provide the other Party within ten (10)
business days after the Effective Date evidence of all insurance required hereunder, and thereafter at any time any insurance
policy covered in this Section 9 is renewed, or upon request by a Party, during the Term. The provisions of Section
9 shall not be deemed to limit the liability of a Party hereunder or limit any rights that a Party may have including rights
of indemnity or contribution.

 

10. Indemnification.

 

10.1
 Company. Company shall indemnify, defend and hold harmless GRS, and its members
and Affiliates, and its and their respective members, shareholders, officers, managers, directors, employees, agents, successors,
and assigns, as the case may be, from and against any and all third party losses, damages, injuries, causes of action, claims,
demands, and expenses (including reasonable legal fees and expenses) (the “Losses”), regardless of nature or type
of such third party claim, whether actual or alleged, based upon tort, breach of contract, or other third party claims, if and
to the extent arising out of, resulting from, or related to (i) any act, omission, or default in the performance of obligations
of Company pursuant to this Agreement or breach of any covenant, agreement, representation or warranty by Company under this Agreement;
(ii) Company Excluded Activities (as such term is hereinafter defined); (iii) any materials provided by Company or its employees,
agents or representatives and used by GRS in any of the GRS Property; (iv) infringement of United States proprietary rights or
intellectual property rights of any third party by Company Consumer Products or any other Company consumer service; or (v) any
claims or actions arising or resulting from the marketing, sale, distribution, or use by Company of Company Consumer Products
including claims or actions relating to any governmental or regulatory investigations, inquiries, and actions; except (x) with
respect to (iii) to the extent such third party claim is caused by any use, modification or alteration of materials by or on behalf
of GRS not under the direction or request of Company and/or in a manner not authorized under this Agreement (the “GRS
Excluded Activities”) or (y) if the Losses arise out of, result from, or relate to the gross negligence or intentional
misconduct of GRS.

 

    11

     

    

 

10.2
 GRS. GRS shall indemnify, defend and hold harmless Company and its Affiliates
and its and their respective members, shareholders, officers, managers, directors, employees, agents, successors, and assigns,
as the case may be, from and against Losses, regardless of nature or type of such third party claim, whether actual or alleged,
based upon tort, breach of contract, or other third party claims, if and to the extent arising out of, resulting from, or related
to (i) any act, omission, or default in the performance of the obligations of GRS pursuant to this Agreement or breach of any
covenant, agreement, representation, or warranty by GRS under this Agreement; (ii) the GRS Excluded Activities; or (iii) any materials
created or provided by, for, or on behalf of GRS in providing the GRS Services, including the GRS Property; except with respect
to (iii) to the extent such third party claim is caused by any use, modification or alteration of the GRS Property or GRS Services
by or on behalf of Company in a manner not authorized under this Agreement (the “Company Excluded Activities”);
and except to the extent the Losses arise out of, result from, or relate to the gross negligence or intentional misconduct of
Company.

 

10.3
 Indemnification Procedures. In the event of a claim for indemnification based
on a third-Party claim, the Party seeking indemnification agrees to: (i) promptly notify the indemnifying Party of any matters
in respect of which the indemnity may apply and of which the indemnified Party has knowledge; provided that any failure by the
Party seeking indemnification to provide prompt notice shall not excuse the indemnifying Party of its indemnification obligation
hereunder unless, and solely to the extent that, a court determines that such failure materially prejudices the indemnifying Party’s
ability to defend or settle any such claim; (ii) give the indemnifying Party full opportunity to control the response thereto
and the defense thereof, including any agreement relating to the settlement thereof, provided that the indemnifying Party shall
not settle any such claim or action unless such settlement either (a) includes an unconditional release of the indemnified Party
from all liability on all claims that are the subject matter of such proceeding or (b) is consented to in writing by the indemnified
Party; and (iii) cooperate with the indemnifying Party, at the indemnifying Party’s cost and expense, in the defense or
settlement thereof. The indemnified Party may participate, at its own expense, in such defense and in any settlement discussions
directly or through counsel of its choice on a monitoring, non-controlling basis. In the event the indemnifying Party does not
assume control of the response and defense of a claim pursuant to clause (ii) of this Section 10.3, the indemnified Party
shall have the right to assume control of the defense of such claim at the expense of the indemnifying Party.

 

11. Limitation
of Liability; Waiver of Certain Damages.

 

11.1 LIMITATION
OF LIABILITY. EXCEPT FOR LIABILITY ARISING OUT OF (A) A BREACH OF SECTION 6 ABOVE, OR (B) A PARTY’S WILLFUL MISCONDUCT,
UNDER NO CIRCUMSTANCES SHALL THE LIABILITY OF A PARTY HERETO OR ITS AFFILIATES, AND ITS AND THEIR RESPECTIVE MEMBERS, SHAREHOLDERS,
OFFICERS, MANAGERS, DIRECTORS, EMPLOYEES, AGENTS, SUCCESSORS AND ASSIGNS, AS THE CASE MAY BE, HEREUNDER EXCEED, IN THE AGGREGATE,
AN AMOUNT EQUAL TO THE MONTHLY FEES ACTUALLY RECEIVED BY GRS DURING THE TWELVE (12) MONTH PERIOD IMMEDIATELY PRECEDING THE MOST
RECENT EVENT GIVING RISE TO THE CLAIM (OR SUCH SHORTER PERIOD IF THE EVENT OCCURS DURING THE FIRST TWELVE (12) MONTHS OF THE TERM).

 

    12

     

    

11.2 WAIVER
OF CERTAIN DAMAGES. EXCEPT FOR LIABILITY ARISING OUT OF (A) A BREACH OF SECTION 6 ABOVE, OR (B) A PARTY’S WILLFUL
MISCONDUCT, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER, WHETHER IN CONTRACT, TORT (INCLUDING NEGLIGENCE), WARRANTY
OR OTHERWISE, FOR ANY INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL, EXEMPLARY OR PUNITIVE DAMAGES (INCLUDING, WITHOUT LIMITATION,
DAMAGES FOR LOSS OF PROFITS) ARISING OUT OF OR RELATING TO THIS AGREEMENT.

 

12. Equitable
Relief. Each of the Parties recognizes, acknowledges, and agrees that any remedy at law for Company’s breach of the
provisions of Sections 4, 5.3(ii), or 6, or for GRS’s breach of Section 6, may be inadequate. Accordingly,
the Parties agree that in the event of any such breach or threatened breach, the other Party will have available, in addition
to any other right or remedy otherwise available, the right to seek preliminary and permanent injunctive relief and other equitable
relief to prevent or curtail any such breach or threatened breach and to specific performance of any covenant contained herein,
in order that the breach or threatened breach of such provisions may be effectively restrained. Each Party further agrees that
it will not assert as a claim or disclose in any action or proceeding to enforce any provision of Sections 4, 5.3(ii), or
6 that the other Party has or had an adequate remedy at law. No specification in this Section 12 of a specific legal
or equitable remedy shall be construed as a waiver or prohibition against the pursuit of other legal or equitable remedies in
the event of a breach or threatened breach of Sections 4, 5.3(ii), or 6.

 

13. Complete
Agreement; Amendment. This Agreement (i) shall become effective only upon execution by both Parties, (ii) is, together with
the Exhibits attached hereto, the entire agreement between the Parties regarding the subject matter hereof, and (iii) supersedes
all prior and contemporaneous oral and written understandings and agreements pertaining thereto, including the Deal Memo. No amendment
hereto shall be effective unless in writing and executed by the Parties’ authorized representatives.

 

14.
 Assignments. Neither Party shall have the right to assign this Agreement or any
rights or obligations hereunder, in whole or in part, without the prior written consent of the other Party; provided that either
Party may assign its rights and obligations hereunder by operation of law in a merger or pursuant to a share exchange involving
the transfer of more than fifty percent (50%) of the outstanding voting power of such Party or in connection with the sale of
all or substantially all of such Party’s assets.

 

15. Notice.
Any notice, request, payment, or other communication under this Agreement shall be in writing and shall be given or made by physical
delivery, confirmed facsimile, overnight carrier (e.g., Federal Express) or by U.S. mail, registered or certified mail
(postage prepaid, return receipt requested, as applicable) addressed to the appropriate Party. All such notices shall be addressed
as follows (provided that a Party’s inadvertent failure to comply with the provisions of this Section 15 shall not
be deemed a material breach of this Agreement):

 

	If to GRS:	GRS, LLC	 	 
	 	c/o Guthy-Renker Ventures, LLC	 	 
	 	100 North
Pacific Coast Highway, 19th Floor

	 	 
	 	El Segundo, CA 90245	 	 
	 	Fax:  310-581-3443	 	 
	 	Attention: Boris Shimanovsky	 	 

 

    13

     

    

 

	With
    a copy to:	Guthy-Renker
    Ventures, LLC	 	 
	 	100
    North Pacific Coast Highway, 19th Floor	 	 
	 	El
    Segundo, CA 90245	 	 
	 	Fax:  310-581-3443	 	 
	 	Attention:
    General Counsel	 	 
	 	 	 	 
	If
    to Company:	G
    Medical Innovations Holdings LTD.	and
    to:	 
	 	5
    Oppenheimer St.	1500
    S Lake Side	 
	 	Rehovot
    7670105, Israel	Bannockburn,
                                         IL 60015

	 

 

16.
 Applicable Law. This Agreement shall be governed by and construed under the laws
of the State of California, without giving effect to its conflict of laws principles.

 

17. Dispute
Resolution. Except as otherwise provided in this Agreement (including Section 12), Company and GRS will attempt in
good faith to resolve through negotiation any dispute, claim or controversy arising out of or relating to this Agreement. Either
Party may initiate negotiations of any dispute by providing written notice to the other Party, setting forth the subject of the
dispute. The recipient of such notice will respond in writing within ten (10) calendar days with a statement of its position on
and recommended solution to the dispute. If the dispute is not resolved by this exchange of correspondence, then representatives
of each Party with full settlement authority will meet at a mutually agreeable time and place within thirty (30) calendar days
of the date of the initial notice in order to exchange relevant information and perspectives, and to attempt to resolve the dispute.
If the dispute is not resolved by these negotiations, the matter will be submitted for mediation administered by the JAMS Arbitration
and Mediation Services (“JAMS”) unless otherwise agreed to by the Parties in writing. The Parties shall share
any fees or expenses of the mediator. If the matter is not resolved through mediation, then the Parties shall be free to avail
themselves of any and all legal remedies; provided that any legal action brought under this Agreement shall be brought in the
state or Federal courts located in the Los Angeles County, California. The prevailing Party in any such action shall be entitled
to reimbursement of reasonable attorneys’ fees and costs.

 

18.
 Interpretation. Titles of the Sections hereof are for reference only and are
not a part of nor to be used in construction of the terms and conditions this Agreement. For all purposes of and under this Agreement,
(a) the words “include” and “including” shall be deemed to be immediately followed by the word “without
limitation”, and (b) except as otherwise set forth herein, references to “dollars” or “$” shall
be to U.S. dollars.

 

19.
 Severability. If any provision of this Agreement shall be judicially determined
to be invalid, illegal, or unenforceable, the validity, legality, and enforceability of the remaining provisions shall not in
any way be affected or impaired thereby.

 

20.
 Independent; No Joint Venture. GRS and Company agree that the relationship between
them is that of independent contractors, and not as joint venturers or partners. This Agreement is not intended to create any
joint venture or partnership arrangement between the Parties. Each Party shall be responsible for the timely payment of all taxes
and all withholdings, deductions, and payments required by law with respect to its own operations.

 

    14

     

    

 

21.
 Disclaimers; No Warranties. GRS and its Affiliates make no express or implied
warranties, guarantees, or guarantees of success with respect to the GRS Services. TO THE MAXIMUM EXTENT PERMITTED BY LAW, GRS
AND ITS AFFILIATES DISCLAIM ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO ANY WARRANTIES OF MERCHANTABILITY
OR FITNESS FOR A PARTICULAR PURPOSE.

 

22. Counterparts.
This Agreement may be executed in multiple counterparts, each of which shall be deemed an original, but all such counterparts
taken together shall constitute one and the same Agreement. Delivery of an executed counterpart of a signature page to this Agreement
by electronic delivery in PDF format shall be as effective as delivery of a manually executed counterpart of this Agreement and
shall be sufficient to bind the Parties to the terms and conditions of this Agreement.

 

23. Further
Assurances. Each Party shall execute and deliver, or cause to be executed and delivered, such additional or supplemental certificates,
instruments, and documents, and take such other action as reasonably may be required to more effectively carry out the intention
of the Parties and facilitate the performance of this Agreement.

 

24. Public
Announcement. Except as required by applicable law, neither Party shall issue any press release or public announcement relating
to the subject matter or terms of this Agreement or any other transaction documents entered into in connection herewith or disclose
that the Parties have entered into a business relationship relating to the transactions contemplated hereby without the prior
written consent of the other Party. The Parties hereto shall use commercially reasonable efforts to develop a joint communications
plan with respect to the subject matter of this Agreement and each Party shall use its commercially reasonable efforts to ensure
that all press releases and other public statements with respect to the subject matter of this Agreement shall be consistent with
such joint communications plan.

25
 Approvals. To the extent a Party makes any written request of the other Party
to approve or consent to any actions under this Agreement which require approval hereunder, the Party receiving such request agrees
to respond in writing to such request within five (5) business days. Failure of a Party to timely respond shall be deemed an approval
of such request.

 

26. Waiver.
No failure to exercise and no delay in exercising on the part of either of the Parties, any right, power, or privilege under this
Agreement shall operate as a waiver of it, nor shall any single or partial exercise of any other right, power, or privilege preclude
any other or further exercise of it or the exercise of any other right, power or privilege.

 

[Remainder
of page intentionally left blank]

 

    15

     

    

 

IN
WITNESS WHEREOF, the Parties’ respective authorized representatives have signed this Media and Marketing Services Agreement
to be effective as of the Effective Date.

 

	 	GRS, LLC, 
	 	a Delaware limited liability company
	 	 	 	 
	 	By: 	/s/ Boris Shimanovsky
	 	 	Name: 	Boris Shimanovsky
	 	 	Title:	President
	 	 	 
	 	G Medical Innovations Holdings LTD.
	 	Cayman Islands exempted company 
	 	 
	 	By: 	/s/ Yacov Geva
	 	 	Name:  	Yacov Geva
	 	 	Title: 	Chief Executive Officer

 

    16

     

    

 

EXHIBIT
A

 

Form
of Warrant

 

See
attached

 

    17

     

    

 

THIS
WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND
UNTIL REGISTERED UNDER THE SECURITIES ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE, PLEDGE
OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.

 

G
MEDICAL INNOVATIONS HOLDINGS LTD.

 

COMMON
STOCK WARRANT

 

	Company: 	G MEDICAL INNOVATIONS HOLDINGS LTD., a Cayman Islands exempted company (the “Company”)
	 	 
	Number of Shares: 	____________ (the “Shares”)
	 	 
	Type/Series of Stock: 	Common stock of the Company (“Common Stock”)1
	 	 
	Vesting:	_______ Shares2
shall be fully vested upon the Issue Date (the “Initial Tranche”), and an additional _______ Shares3
shall vest as of September 18, 2021 (the “Second Tranche”).
	 	 
	Warrant Price: 	The Initial Tranche of the Warrant (the “Warrant”) shall have an exercise price equal to Five Cents AUD (AUD $0.05) per Share (subject to adjustment on the terms and conditions set forth herein).  The Second Tranche of the Warrant shall have an exercise price equal to the lessor of a Fifty Percent (50%) discount to the Company’s planned NASDAQ Initial Public Offering price or a Fifty Percent (50%) discount to the Company’s share price on the date of vesting.
	 	 
	Issue Date: 	_______________
	 	 
	Expiration Date: 	Nine years from the Issue Date. See also Section 5.1(b).
	 	 
	Media and Marketing 	 
	Services Agreement:	This Warrant is issued in connection with that certain Media and Marketing Services Agreement of even date herewith between GRS, LLC (“GRS”) and the Company (as the same may be amended, modified, supplemented or restated, the “Agreement”).

 

 

		1	Number of shares to equal 5% of the Company’s outstanding
Common Stock (calculated on a fully diluted, as converted basis).

		2	To equal 50% of the Shares.

		3	To equal 50% of the Shares.

 

    18

     

    

 

THIS
WARRANT CERTIFIES THAT, for good and valuable consideration, GRS (together with any successor or permitted assignee or transferee
of this Warrant or of any shares issued upon exercise hereof, “Holder”) is entitled to purchase the number
of fully paid and non-assessable shares (the “Shares”) of Common Stock (the “Class”) of
the Company at the above-stated Warrant Price, all as set forth above and as adjusted pursuant to Section 2 of this Warrant, subject
to the provisions and upon the terms and conditions set forth in this Warrant.

 

This
Warrant may be exercised as to the Shares which have vested as set forth above (“Vested Shares”). Any Shares
which remain unvested (“Unvested Shares”) as of the expiration or earlier termination of the Agreement and
do not automatically vest upon such date in accordance with the terms and conditions of the Agreement shall be void thereafter.

 

Section
1. EXERCISE.

 

1.1 Method
of Exercise. Holder may at any time and from time to time exercise this Warrant, in whole or in part, by delivering to the
Company the original of this Warrant together with a duly executed Notice of Exercise in substantially the form attached hereto
as Appendix I and, unless Holder is exercising this Warrant pursuant to a cashless exercise set forth in Section 1.2,
a check, wire transfer of same-day funds (to an account designated by the Company), or other form of payment acceptable to the
Company for the aggregate Warrant Price for the Vested Shares being purchased.

 

1.2 Cashless
Exercise. On any exercise of this Warrant, in lieu of payment of the aggregate Warrant Price in the manner as specified in
Section 1.1 above, but otherwise in accordance with the requirements of Section 1.1, Holder may elect to receive Shares
equal to the value of this Warrant, or portion hereof as to which this Warrant is being exercised. Thereupon, the Company shall
issue to Holder such number of fully paid and non-assessable Shares as are computed using the following formula:

 

X
= Y(A-B)/A

 

where:

 

		X
                                         =	the
                                         number of Shares to be issued to Holder;

 

		Y
                                         =	the
                                         number of Vested Shares with respect to which this Warrant is being exercised (inclusive
                                         of the Shares surrendered to the Company in payment of the aggregate Warrant Price);

 

		A
                                         =	the
                                         fair market value (as determined pursuant to Section 1.3 below) of one Share; and

 

		B
                                         =	the
                                         Warrant Price (as adjusted to the date of such calculation).

 

    19

     

    

 

1.3 Fair
Market Value. If the Company’s Common Stock is then traded or quoted on a United States national securities exchange,
inter-dealer quotation system or over-the-counter market (a “Trading Market”), the fair market value of a Share
shall be the VWAP (as defined below) of the Common Stock on the Trading Day (as defined below) immediately before the date on
which Holder delivers this Warrant together with its Notice of Exercise to the Company. If the Company’s Common Stock is
not traded in a Trading Market, the Board of Directors of the Company shall determine the fair market value of a Share in its
reasonable good faith judgment.

 

1.4 Certain
Definitions. In addition to the terms defined elsewhere in this Warrant, the following terms have the following meanings:

 

(a) “Board
of Directors” means the board of directors of the Company.

 

(b) “Business
Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or
the Cayman Islands any day on which banking institutions in the State of California or the Cayman Islands are authorized or required
by law or other governmental action to close.

 

(c) “Trading
Day” means a day on which the principal Trading Market is open for trading.

 

(d) “VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then
listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest
preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based
on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading
Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX
as applicable, or (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common
Stock are then reported in the “Pink Sheets” published by OTC Markets Group, Inc. (or a similar organization or agency
succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported.

 

1.5 Delivery
of Certificate and New Warrant. As promptly as reasonably practicable after the date Holder exercises this Warrant in the
manner set forth in Section 1.1 or 1.2 above, the Company shall deliver to Holder a certificate representing the Shares issued
to Holder upon such exercise and, if this Warrant has not been fully exercised and has not expired, a new warrant of like tenor
representing the Shares not so acquired.

 

1.6 Replacement
of Warrant. On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of
this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in
form, substance and amount to the Company or, in the case of mutilation, on surrender of this Warrant to the Company for cancellation,
the Company shall, within a reasonable time, execute and deliver to Holder, in lieu of this Warrant, a new warrant of like tenor
and amount.

 

    20

     

    

 

1.7 Treatment
of Warrant Upon Acquisition of Company.

 

(a) Acquisition.
For the purpose of this Warrant, “Acquisition” means any transaction or series of related transactions involving:
(i) the sale, lease, exclusive license, or other disposition of all or substantially all of the assets of the Company (ii) any
merger or consolidation of the Company into or with another person or entity (other than a merger or consolidation effected exclusively
to change the Company’s domicile), or any other corporate reorganization, in which the stockholders of the Company in their
capacity as such immediately prior to such merger, consolidation or reorganization, own less than a majority of the Company’s
(or the surviving or successor entity’s) outstanding voting power immediately after such merger, consolidation or reorganization;
or (iii) any sale or other transfer by the stockholders of the Company of shares representing at least a majority of the
Company’s then-total outstanding combined voting power.

 

(b) Treatment
of Warrant at Acquisition. In the event of an Acquisition, either (i) Holder shall exercise this Warrant pursuant to
Section 1.1 and/or 1.2 and such exercise will be deemed effective immediately prior to and contingent upon the consummation
of the Acquisition or (ii) if Holder elects not to exercise the Warrant, this Warrant will expire immediately prior to the
consummation of such Acquisition. In the event the Holder does not notify the Company in writing as to whether it intends to exercise
the Warrant prior to and contingent upon the consummation of the Acquisition then if, immediately prior to the Acquisition, the
fair market value of one Share (or other security issuable upon the exercise hereof) as determined in accordance with Section 1.3
above would be greater than the Warrant Price in effect on such date, then this Warrant shall automatically be deemed on and as
of such date to be exercised pursuant to Section 1.2 above as to all Vested Shares for which it shall not previously have
been exercised, and the Company shall promptly notify Holder of the number of Shares (or such other securities) issued upon such
exercise to Holder and Holder shall be deemed to have restated each of the representations and warranties in Section 4 of the
Warrant as the date thereof.

 

(c) Notice.
The Company shall provide Holder with written notice of any proposed Acquisition (together with such reasonable information
as Holder may reasonably require regarding the treatment of this Warrant in connection with such contemplated Acquisition giving
rise to such notice), which is to be delivered to Holder not less than seven Business Days prior to the closing of the proposed
Acquisition.

 

Section
2. ADJUSTMENTS TO THE SHARES AND WARRANT PRICE.

 

2.1 Stock
Dividends, Splits, Etc. If the Company declares or pays a dividend or distribution on the outstanding shares of the Class
payable in Common Stock or other securities or property (other than cash), then upon exercise of this Warrant, for each Share
acquired, Holder shall receive, without additional cost to Holder, the total number and kind of securities and property which
Holder would have received had Holder owned the Shares of record as of the date the dividend or distribution occurred. If the
Company subdivides the outstanding shares of the Class by reclassification or otherwise into a greater number of shares, the number
of Shares purchasable hereunder shall be proportionately increased and the Warrant Price shall be proportionately decreased. If
the outstanding shares of the Class are combined or consolidated, by reclassification or otherwise, into a lesser number of shares,
the Warrant Price shall be proportionately increased and the number of Shares shall be proportionately decreased.

 

    21

     

    

 

2.2 Reclassification,
Exchange, Combinations or Substitution. Upon any event whereby all of the outstanding shares of the Class are reclassified,
exchanged, combined, substituted, or replaced for, into, with or by Company securities of a different class and/or series, then
from and after the consummation of such event, this Warrant will be exercisable for the number, class and series of Company securities
that Holder would have received had the Shares been outstanding on and as of the consummation of such event, and subject to further
adjustment thereafter from time to time in accordance with the provisions of this Warrant. The provisions of this Section 2.2
shall similarly apply to successive reclassifications, exchanges, combinations substitutions, replacements or other similar events.

 

2.3 No
Fractional Share. No fractional Share shall be issuable upon exercise of this Warrant and the number of Shares to be issued
shall be rounded down to the nearest whole Share. If a fractional Share interest arises upon any exercise of the Warrant, the
Company shall eliminate such fractional Share interest by paying Holder in cash the amount computed by multiplying the fractional
interest by (i) the fair market value (as determined in accordance with Section 1.3 above) of a full Share, less (ii) the
then-effective Warrant Price.

 

2.4 Notice/Certificate
as to Adjustments. Upon each adjustment of the Warrant Price, Class, and/or number of Shares, the Company, at the Company’s
expense, shall notify Holder in writing within a reasonable time setting forth the adjustments to the Warrant Price, Class and/or
number of Shares and facts upon which such adjustment is based. The Company shall, upon written request from Holder, furnish Holder
with a certificate of its Chief Financial Officer, including computations of such adjustment and the Warrant Price, Class and
number of Shares in effect upon the date of such adjustment.

 

Section
3. REPRESENTATIONS AND COVENANTS OF THE COMPANY.

 

3.1 Representations
and Warranties. The Company represents and warrants to, and agrees with, Holder as follows:

 

(a) The
initial Warrant Price referenced on the first page of this Warrant is not greater than the price per share at which the Company
most recently sold shares of its capital stock in an arms-length equity financing transaction in which at least $1,000,000 of
capital stock was sold.

 

(b) All
Shares which may be issued upon the exercise of this Warrant, and all securities, if any, issuable upon conversion of the Shares,
shall, upon issuance, be duly authorized, validly issued, fully paid and non-assessable, and free of any liens and encumbrances
except for restrictions on transfer provided for herein or under applicable federal and state securities laws or restrictions
under any Agreement among the Company and Holder. The Company covenants that it shall at all times cause to be reserved and kept
available out of its authorized and unissued capital stock such number of shares of the Class, Common Stock and other securities
as will be sufficient to permit the exercise in full of this Warrant and the conversion of the Shares into Common Stock or such
other securities. The Company agrees that its issuance of this Warrant shall constitute full authority to its officers who are
charged with the duty of executing stock certificates to execute and issue the necessary certificates for Shares upon the exercise
of this Warrant in the manner set forth in Section 1.1 or 1.2 above.

 

    22

     

    

 

Section
4. REPRESENTATIONS, WARRANTIES OF THE HOLDER.

 

The
Holder represents and warrants to the Company as follows:

 

4.1 Purchase
for Own Account. This Warrant and the securities to be acquired upon exercise of this Warrant by Holder are being acquired
for investment for Holder’s account, not as a nominee or agent, and not with a view to the public resale or distribution
within the meaning of the Securities Act. Holder also represents that it has not been formed for the specific purpose of acquiring
this Warrant or the Shares.

 

4.2 Disclosure
of Information. Holder is aware of the Company’s business affairs and financial condition and has received or has had
full access to all the information it considers necessary or appropriate to make an informed investment decision with respect
to the acquisition of this Warrant and its underlying securities. Holder further has had an opportunity to ask questions and receive
answers from the Company regarding the terms and conditions of the offering of this Warrant and its underlying securities and
to obtain additional information (to the extent the Company possessed such information or could acquire it without unreasonable
effort or expense) necessary to verify any information furnished to Holder or to which Holder has access.

 

4.3 Investment
Experience. Holder understands that the purchase of this Warrant and its underlying securities involves substantial risk.
Holder has experience as an investor in securities of companies in the development stage and acknowledges that Holder can bear
the economic risk of such Holder’s investment in this Warrant and its underlying securities and has such knowledge and experience
in financial or business matters that Holder is capable of evaluating the merits and risks of its investment in this Warrant and
its underlying securities and/or has a preexisting personal or business relationship with the Company and certain of its officers,
directors or controlling persons of a nature and duration that enables Holder to be aware of the character, business acumen and
financial circumstances of such persons.

 

4.4 Accredited
Investor Status. Holder is an “accredited investor” within the meaning of Regulation D promulgated under the Securities
Act by virtue of being an entity, all of whose equity owners are “accredited investors” within the meaning of Regulation
D promulgated under the Securities Act.

 

4.5 The
Securities Act. Holder understands that this Warrant and the Shares issuable upon exercise hereof have not been registered
under the Securities Act or under the securities or laws of any state of the United States, and have been and will be offered
and sold in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature
of Holder’s investment intent as expressed herein, and further that this Warrant may not be exercised absent registration
of the underlying Shares under the Securities Act and applicable state securities laws unless an exemption from such registration
requirements is available. Holder understands that this Warrant and the Shares issued upon any exercise hereof must be held indefinitely
as “Restricted Securities” (as such term is defined in Rule 144 under the Securities Act) unless subsequently registered
under the Securities Act and qualified under applicable state securities laws, or unless exemption from such registration and
qualification are otherwise available. Holder is aware of the provisions of Rule 144 promulgated under the Securities Act.

 

    23

     

    

 

4.6 No
Voting Rights. Holder, as a Holder of this Warrant, will not have any voting rights until the exercise of this Warrant.

 

Section
5. MISCELLANEOUS.

 

5.1 Term
and Automatic Conversion Upon Expiration.

 

(a) Term.
Subject to the provisions of Section 1.7 above, this Warrant is exercisable in whole or in part at any time and from time
to time on or before 6:00 PM, Eastern Time, on the Expiration Date and shall be void thereafter.

 

(b) Automatic
Cashless Exercise upon Expiration. In the event that, upon the Expiration Date, the fair market value of one Share (or other
security issuable upon the exercise hereof) as determined in accordance with Section 1.3 above is greater than the Warrant
Price in effect on such date, then this Warrant shall automatically be deemed on and as of such date to be exercised pursuant
to Section 1.2 above as to all Vested Shares (or such other securities) for which it shall not previously have been exercised,
and the Company shall, within a reasonable time, deliver a certificate representing the Shares (or such other securities) issued
upon such exercise to Holder.

 

5.2 Legends.
The Shares (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) shall be imprinted with
a legend in substantially the following form:

 

THE
SHARES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND
UNTIL REGISTERED UNDER THE SECURITIES ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER, SUCH OFFER, SALE, PLEDGE
OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.

 

THE
SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE, INCLUDING A LOCK-UP PERIOD IN
THE EVENT OF A PUBLIC OFFERING, AS SET FORTH IN THE WARRANT PURSUANT TO WHICH THESE SHARES WERE ISSUED, A COPY OF WHICH MAY BE
OBTAINED AT THE PRINCIPAL OFFICE OF THE COMPANY.

 

    24

     

    

 

5.3 Transfer
Restrictions.

 

(a) Before
any proposed sale, pledge, or transfer of any of this Warrant or any Shares issuable upon exercise of this Warrant (the Warrant
and the Shares Issuable upon Exercise of the Warrant shall be collectively referred to herein as “Restricted Securities”),
unless there is in effect a registration statement under the Securities Act covering the proposed transaction, Holder shall give
notice to the Company of Holder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the
manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably requested by the Company,
shall be accompanied at Holder’s expense by either (i) a written opinion of legal counsel of recognized standing who shall,
and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to the Company, to the effect that the proposed
transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC
to the effect that the proposed sale, pledge, or transfer of such Restricted Securities without registration will not result in
a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory
to counsel to the Company to the effect that the proposed sale, pledge, or transfer of the Restricted Securities may be effected
without registration under the Securities Act, whereupon Holder shall be entitled to sell, pledge, or transfer the securities
in accordance with the terms of the notice given by Holder to the Company. The Company will not require such a legal opinion or
“no action” letter (i) in any transaction in compliance with SEC Rule 144, if available, or (ii) in any transaction
in which Holder distributes the Warrant or Shares to an Affiliate of such Holder for no consideration. Each certificate evidencing
the Restricted Securities transferred as above provided shall bear, except if such transfer is made pursuant to SEC Rule 144,
the appropriate restrictive legend(s) set forth above to the extent applicable.

 

(b) The
Restricted Securities may not be transferred or assigned in whole or in part to any person or entity who is a competitor of the
Company, as determined in good faith by the Company’s Board of Directors.

 

5.4 Notices.
All notices and other communications hereunder from the Company to Holder, or vice versa, shall be deemed delivered and effective
(i) when given personally, (ii) on the third (3rd) Business Day after being mailed by first-class registered
or certified mail, postage prepaid, (iii) upon actual receipt if given by facsimile or electronic mail and such receipt is
confirmed in writing by the recipient, or (iv) on the first Business Day following delivery to a reliable overnight courier
service, courier fee prepaid, in any case at such address as may have been furnished to the Company or Holder, as the case may
be, in writing by the Company or such Holder from time to time in accordance with the provisions of this Section 5.4. All
notices to Holder shall be addressed as follows until the Company receives notice of a change of address in connection with a
transfer or otherwise:

 

GRS
LLC

c/o
Guthy-Renker LLC

100
North Sepulveda Boulevard, 19th Floor

El
Segundo, CA 90245

Fax:
310-581-3443

Attention:
Business Affairs

 

    25

     

    

 

With
a copy to:

 

Guthy-Renker
LLC

100
North Sepulveda Boulevard, 19th Floor

El
Segundo, CA 90245

Fax:
310-581-3443

Attention:
General Counsel

Email:
SBlackman@guthy-renker.com

 

Notice
to the Company shall be addressed as follows until Holder receives notice of a change in address:

 

G
Medical Innovations Holdings LTD.

[________]

[________]

Attn:Yacov
Geva

Fax:

Email:

 

5.5 Waiver.
This Warrant and any term hereof may be changed, waived, discharged or terminated (either generally or in a particular instance
and either retroactively or prospectively) only by an instrument in writing signed by the party against which enforcement of such
change, waiver, discharge or termination is sought.

 

5.6 Attorney’s
Fees. In the event of any dispute between the parties concerning the terms and provisions of this Warrant, the party prevailing
in such dispute shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable attorneys’
fees.

 

5.7 Counterparts;
Facsimile/Electronic Signatures. This Warrant may be executed in counterparts, all of which together shall constitute one
and the same agreement. Any signature page delivered electronically or by facsimile shall be binding to the same extent as an
original signature page with regards to any agreement subject to the terms hereof or any amendment thereto.

 

5.8 Governing
Law. This Warrant shall be governed by and construed in accordance with the laws of the State of California, without giving
effect to its principles regarding conflicts of law.

 

5.9 Headings.
The headings in this Warrant are for purposes of reference only and shall not limit or otherwise affect the meaning of any provision
of this Warrant.

 

[Remainder
of page left blank intentionally]

[Signature
page follows]

 

    26

     

    

 

IN
WITNESS WHEREOF, the parties have caused this Warrant to Purchase Stock to be executed by their duly authorized representatives
effective as of the Issue Date written above.

 

	“COMPANY”	 
	 	 	 
	G
    MEDICAL INNOVATIONS HOLDINGS LTD.	 
	 	 	 
	By:	                              	 
	Name: 	 	 
		(Print)	 
	Title:	 	 
	 	 	 
	“HOLDER”	 
	 	 	 
	GRS
    LLC	 
	 	 	 
	By:	 	 
	Name:	 	 
		(Print)	 
	Title:	 	 

 

    27

     

    

 

APPENDIX
I

 

NOTICE
OF EXERCISE

 

1. The
undersigned Holder hereby exercises its right purchase ___________ shares of the Common Stock of G Medical Innovations Holdings
LTD. (the “Company”) in accordance with the attached Warrant, and tenders payment of the aggregate Warrant
Price for such shares as follows:

 

[   
]     check in the amount of $________ payable to order of the Company enclosed herewith

 

[   

]     Wire transfer of immediately available funds to the Company’s account

 

[   

]     Cashless Exercise pursuant to Section 1.2 of the Warrant

 

[   

]     Other [Describe] __________________________________________

 

2. Please
issue a certificate or certificates representing the Shares in the name specified below:

 

___________________________________________

            Holder’s Name

 

___________________________________________

 

___________________________________________

            (Address)

 

3. By
its execution below and for the benefit of the Company, Holder hereby restates each of the representations and warranties in Section
4 of the Warrant to Purchase Stock as of the date hereof.

 

HOLDER:

 

_________________________

 

By:_________________________

 

Name:________________________

 

Title:_________________________

 

(Date):_______________________

 

 

28

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00323-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00323-of-00352.parquet"}]]